Patent Grant
12233003
A patient may have limited or impaired mobility such that typical urination processes are challenging or impossible. For example, the patient may have surgery or a disability that impairs mobility. In another example, the patient may have restricted travel conditions such as those experience by pilots, drivers, and workers in hazardous areas. Additionally, fluid collection from the patient may be needed for monitoring purposes or clinical testing.
Bed pans and urinary catheters, such as a Foley catheter, may be used to address some of these circumstances. However, bed pans and urinary catheters have several problems associated therewith. For example, bed pans may be prone to discomfort, spills, and other hygiene issues. Urinary catheters be may be uncomfortable, painful, and may cause urinary tract infections.
Embodiments are directed towards fluid collection assemblies that include at least one length adjusting feature, fluid collection systems including the same, and methods of using the same. In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a distal region, at least one proximal end region spaced from the distal region, at least one intermediate portion extending from the at least one proximal end region to the distal region, and at least one length adjusting feature extending from the at least one proximal end region towards the distal region. The at least one length adjusting feature is configured to allow a length of the fluid collection assembly to change. The fluid collection assembly also includes a fluid impermeable barrier forming at least a portion of the distal region, the at least one proximal end region, and the at least one intermediate portion. The fluid impermeable barrier at least defining a chamber, an opening at the proximal end region, and a fluid outlet. The fluid collection assembly further includes at least one porous material disposed in the chamber.
In an embodiment, a fluid collection assembly is disclosed. The fluid collection assembly includes a fluid storage container configured to hold one or more bodily fluids. The fluid collection assembly also includes a fluid collection assembly. The fluid collection assembly includes a distal region, at least one proximal end region spaced from the distal region, at least one intermediate portion extending from the at least one proximal end region to the distal region, and at least one length adjusting feature extending from the at least one proximal end region towards the distal region. The at least one length adjusting feature is configured to allow a length of the fluid collection assembly to change. The fluid collection assembly also includes a fluid impermeable barrier forming at least a portion of the distal region, the at least one proximal end region, and the at least one intermediate portion. The fluid impermeable barrier at least defining a chamber, an opening at the proximal end region, and a fluid outlet. The fluid collection assembly further includes at least one porous material disposed in the chamber. The fluid collection system further includes a vacuum source fluidly coupled to one or more of the fluid storage container or the fluid collection assembly via the conduit. The vacuum source is configured to draw fluid from the fluid collection assembly via the conduit.
Features from any of the disclosed embodiments may be used in combination with one another, without limitation. In addition, other features and advantages of the present disclosure will become apparent to those of ordinary skill in the art through consideration of the following detailed description and the accompanying drawings.
The drawings illustrate several embodiments of the present disclosure, wherein identical reference numerals refer to identical or similar elements or features in different views or embodiments shown in the drawings.
Embodiments are directed towards fluid collection assemblies that include at least one length adjusting feature (“LAF”), fluid collection systems including the same, and methods of using the same. An example fluid collection assembly includes a fluid impermeable barrier. The fluid impermeable barrier includes a distal region, at least one proximal end region spaced from the distal region, and at least one intermediate portion extending from the distal region to the proximal end region. The fluid impermeable barrier also defines at least one LAF extending from the proximal end region towards the distal region. The LAF forms one or more lateral edges of the at least one intermediate portion. The LAF allows the length of the fluid collection assembly to change. The ability of the fluid collection assembly to change the length thereof allows a penis of a patient (i.e., an individual using the fluid collection assembly) to be disposed in preferential locations within the fluid collection assembly.
Condom male external catheters (“CMECs”) are devices that are configured to have a penis disposed therein and remove bodily fluids (e.g., urine) that are discharged from the penis. CMECs are generally configured to be used with any penis, regardless of size, to at least one of minimize inventory, allow the penis to become erect without compressing the erect penis, or to prevent the need to use different CMECs depending on whether the penis is flaccid or erect. As such, the CMECs may be configured to be used with penises that, when erect, exhibit an above average size (e.g., an erect penis exhibiting a length greater than 20 cm, measured from a tip of the penis, such as the urethral opening of the penis, to the location where the shaft meets the mons pubis) and, thus, the CMEC may exhibit a length that is greater than 8 inches. However, the CMECs may be used with buried penises, flaccid penises, and penises exhibiting average to below average sizes when erect. Due to the large length of the CMECs, CMECs may exhibit a large distance between the fluid outlet of the CMEC (which is typically at a distal end region of the CMEC) and the penis when the penis is buried, flaccid, or exhibits an average or below average size when erect. The large distance between the penis and the fluid outlet may allow the bodily fluids discharged from the penis to flow in the wrong direction (e.g., away from the fluid outlet) and allow for greater loss of vacuum when a vacuum is used to remove the bodily fluids from the CMECs. Bodily fluids flowing in the wrong direction and/or the loss of vacuum may prevent or inhibit the removal of the bodily fluids from the CMECs which may cause patient discomfort (i.e., the patient remains in contact with the bodily fluids), create unsanitary conditions, and increase the likelihood that the bodily fluids leak from the CMECs.
The fluid collection assemblies disclosed herein may resolve at least some of the above discussed issues of the CMECs. For example, the fluid collection assemblies may exhibit a maximum length that is sufficiently large that the fluid collection assemblies may be used with above average sized erect penises. The fluid collection assemblies may be positioned on a penis such that the urethral opening of the penis is adjacent or at least proximate to the fluid outlet and/or distal region of the fluid collection assemblies. The LAF allows the length of the fluid collection assembly to be effectively changed (e.g., reduced) such that the urethral opening of buried penises, flaccid penises, and erect penis exhibiting average or below average lengths may be positioned adjacent or at least proximate to the fluid outlet and/or the distal region. The LAF allows the portions of the fluid collection assembly to flare outwardly (e.g., increase a width thereof) or be folded to reduce the effective length of the fluid collection assembly. Thus, the LAF may reduce the distance from the urethral opening of the penis and the fluid outlet and/or distal region thereby inhibiting the bodily fluids flowing in the wrong direction and/or inhibiting loss of vacuum.
The distal region 104 is a portion of the fluid collection assembly 100 that is configured to have a urethral opening of the penis 124 disposed adjacent or at least proximate thereof. As such, the distal region 104 (e.g., the porous material 120 of the distal region 104) may receive bodily fluids that are discharged from the urethral opening preferentially and/or before the other portions of the fluid collection assembly 100. For example, a stream of bodily fluids that are omitted from the urethral opening may first contact the distal region 104 of the fluid collection assembly 100 though, it is noted, that the stream may contact other regions of the fluid collection assembly since the penis 124 may be flimsy when flaccid which may allow the bodily fluids to be omitted at a variety of angles even when the urethral opening is adjacent or proximate to the distal region 104.
The distal region 104 includes a portion of the fluid collection assembly 100 that is spaced from proximal end region 106 and the lateral edges 118 of the intermediate portion 108 (e.g., the LAF is not present in the distal region 104). For example, the proximal end region 106 and the lateral edges 118 represent locations through which the bodily fluids may leak from the chamber 110. As such, spacing the distal region 104 from the proximal end region 106 and the lateral edges 118 may minimize the likelihood that the bodily fluids leak from the fluid collection assembly 100.
In an embodiment, as illustrated, the distal region 104 is spaced substantially equidistantly from the all portions of the proximal end region 106 which decreases the likelihood that the bodily fluids may preferentially leak from one portion of the proximal end region 106. In other words, the distal region 104 is located substantially in the middle of the fluid collection assembly 100. In an embodiment, as shown in
In an embodiment, as shown, the distal region 104 may form a sump. The distal region 104 forms a sump when the intermediate portion 108 is fully flared (e.g., the length and maximum width of the fluid collection assembly 100 cannot be smaller and bigger, respectively) and pressed against a flat surface, the portions of the distal region 104 in addition to the fluid outlet 114 may protrude upwardly from the intermediate portion 108. The sump provides a location for at least a portion of the glans (head) of the penis 124 to be disposed in. The sump may optionally provide a location for at least a portion of the shaft of the penis 124 to be disposed in. Providing a location for the glans of the penis to be positioned in may prevent inadvertently compressing the glans of the penis when the fluid collection assembly 100 is secured to the patient, as discussed in more detail below. Further, the sump may increase a distance from the urethral opening of the penis and the proximal end region 106 and the lateral edges 118 thereby decreasing the likelihood that the bodily fluids leak from the chamber 110. In an embodiment, as shown, the sump may exhibit a hollow generally cylindrical shape which generally corresponds to the shape of the penis. In an embodiment, the sump may exhibit a non-cylindrical shape, such as a generally spherical or conical shape. In an embodiment, illustrated in
The fluid outlet 114 may be located on the distal region 104 since the urethral opening of the penis is positioned adjacent to or at least proximate to the distal region 104 thereby reducing the distance between the urethral opening and the fluid outlet 114. However, it is noted that the fluid outlet 114 may be spaced from the distal region 104. In an example, the fluid outlet 114 may be positioned on the intermediate portion 108 at a location that is proximate to (e.g., within about 8 cm, within about 6 cm, within about 5 cm, within about 4 cm, within about 3 cm, within about 2 cm, within about 1 cm, within about 0.5 cm, within 0.25 cm of) the distal region 104. In an example, the fluid outlet 114 may be positioned at or near an expected gravimetric low point of the chamber 110 since at least some of the bodily fluids, once received by the porous material 120, may generally flow in the direction of gravity and the distal region 104 may not be located at the gravimetric low point of the chamber 110.
As previously discussed, the fluid collection assembly 100 includes an LAF. In the illustrated embodiment, the LAF includes a slit 116 that extends from the proximal end region 106 towards (e.g., to) the distal region 104. The slit 116 is configured to control the length of the fluid collection assembly 100. In particular, the slit 116 allows at least a portion of the intermediate portion 108 to be flared (e.g., a width thereof increased) and/or folded back onto the rest of the fluid collection assembly 100. Flaring the intermediate portion 108 or folding the intermediate portion 108 back onto the rest of the fluid collection assembly 100 decreases the effective length of the fluid collection assembly 100. As used herein, the effective length refers to the maximum distance the fluid collection assembly 100 may extend from a base of a penis 124 when at least a portion of the fluid collection assembly 100 is adjacent to the base of the penis 124.
In an embodiment, as shown, the length of the fluid collection assembly 100 may be changed (e.g., decreased) by flaring at least a portion of the intermediate portion 108. Flaring at least a portion of the intermediate portion 108 refers to increasing the width of at least a portion of the intermediate portion 108. The portions of the intermediate portion 108 that flare are referred to as the flared portions 126. For example, the width of the intermediate portion 108 may be increased until flared portion 126 is generally flat or exhibits a shape that generally corresponds to the shape of the region about the penis 124 (e.g., the mons pubis 128, the thighs 130, the testicles (not shown), or other anatomical feature about the penis 124). The flared portion 126 may be formed by moving corresponding portions of the lateral edges 118 (i.e., portions of the lateral edges 118 that are adjacent to each other when the slit 116 is closed) of the intermediate portion 108 away from each other. That is, the flared portion 126 may be formed by increasing a distance between corresponding portions of the lateral edges 118. Increasing the width of the flared portion 126 decreases the length of the fluid collection assembly 100.
In an embodiment, the length of the fluid collection assembly 100 may be changed by folding at least a portion of the intermediate portion 108 back onto itself and/or onto the distal region 104. In such an embodiment, folding the intermediate portion 108 may be formed, at least initially, by flaring at least a portion of the intermediate portion 108 to form a flared portion 126. After forming the flared portion 126, corresponding portions of the lateral edges 118 are brought back together (e.g., a distance between corresponding portions of the lateral edges 118 are decreased) such that an interior of at least a portion of the intermediate portion 108 faces outwardly. For example, folding the intermediate portion 108 may cause a portion of the porous material 120 to be exposed. In other words, the fluid impermeable barrier 102 of the portions of the intermediate portion 108 that were initially flared are positioned proximate to the fluid impermeable barrier 102 of the portions of the fluid collection assembly 100 that were not flared.
The change in the length of the fluid collection assembly 100 is controlled by either flaring or folding all, some, or none of the intermediate portion 108. In particular, increasing the percentage of the intermediate portion 108 that is flared or folded decreases the length of the fluid collection assembly 100. For example, flaring or folding none of the intermediate portion 108 maintains the maximum length of the fluid collection assembly 100, flaring or folding all of the intermediate portion 108 minimizes the length of the collection assembly 100, and flaring or folding only a portion of the intermediate portion 108 causes the fluid collection assembly 100 to exhibit a length that is between the maximum and minimum length. When only a portion of the intermediate portion 108 is flared or folded, greater than 0% to about 20%, about 10% to about 30%, about 20% to about 40%, about 30% to about 50%, about 40% to about 60%, about 50% to about 70%, about 60% to about 80%, about 70% to about 90%, or about 80% to about 99% of a length of the intermediate portion 108 may be flared or folded. Whether all, none, or only some of the intermediate portion 108 is flared or folded may be selected based on the size of the penis 124 that the fluid collection assembly 100 is used with so that the length of the fluid collection assembly 100 allows the urethral opening of the penis 124 to be positioned within, adjacent, or proximate to the distal region 104.
In an embodiment, the fluid collection assembly 100 may exhibit a maximum length that is greater than about 14 cm, such as about 14 cm to about 16 cm when configured to be used with average or below average sized penises only or greater than 16 cm (e.g., about 16 cm to about 20 cm or about 18 cm to about 22 cm) when configured to be used with substantially all penises. The maximum length is the maximum distance from the distal region 104 to the proximal end region 106. The fluid collection assembly 100 may exhibit a final length after at least a portion of the intermediate portion 108 is flared or folded. The final length is less than the maximum length. For example, the final length may be 0 (the distal region 104 does not include a sump) to about 2 cm, about 1 cm to about 3 cm, about 2 cm to about 4 cm, about 3 cm to about 5 cm, about 4 cm to about 6 cm, about 5 cm to about 7 cm, about 6 cm to about 8 cm, about 7 cm to about 9 cm, about 10 cm to about 12.5 cm, about 12 cm to about 15 cm, or about 14 cm to about 20 cm. The final length may be the minimum length of the fluid collection assembly 100 or a length between the maximum length and the minimum length.
In an embodiment, as previously discussed, none or only a portion of the intermediate portion 108 may be flared or folded. In such an embodiment, the fluid collection assembly 100 may include at least one retainer 132. The retainer 132 may be configured to prevent unflared or folded portions of the intermediate portion 108 from flaring or folded (e.g., prevent a distance between corresponding portions of the lateral edges 118 that do not form part of the flared portion 126 from increasing). For example, the retainer 132 may maintain the lateral edges 118 adjacent (e.g., abutting) to each other or overlap portions of the intermediate portion 108, either of which may minimize leakage through the slit 116. The retainer 132 may be positioned on (e.g., attached to, disposed on, fitted around) an exterior surface 134 of the fluid impermeable barrier 102 thereby preventing or at least inhibiting the distance between the corresponding portions lateral edges 118 adjacent to retainer 132 or between the retainer 132 and the distal region 104 from increasing. As such, the retainer 132 may inhibit a length of the fluid collection assembly 100 from changing after positioning the retainer 132 on the exterior surface 134. In an example, the retainer 132 may maintain the lateral edges 118 adjacent (e.g., abutting) to each other.
In an example, the retainer 132 may cause the unflared or unfolded portions of the intermediate portions 108 to overlap. Overlapping the unflared or unfolded portions of the intermediate portions 108 may cause the fluid collection assembly 100 to clasp a shaft of the penis 124 thereby facilitating attachment of the fluid collection assembly 100 to the patient 122. Overlapping the unflared or unfolded portions of the intermediate portions 108 may also decrease the volume of the chamber 110, thereby increasing the likelihood that the bodily fluids discharged into the chamber 110 are received into the porous material 110 instead of leaking. Other structures that may be used to clasp against the shaft of the penis 134, thereby facilitating attachment of the fluid collection assembly 100 to the patient 122 are disclosed in U.S. Provisional Patent Application No. 63/133,892 filed on Jan. 5, 2021, the disclosure of which is incorporated herein, in its entirety, by this reference.
The retainer 132 may include any device that may prevent the distance between corresponding portions of the lateral edges 118 adjacent to the retainer 132 and/or between the retainer 132 and the distal region 104 from increasing. In an example, the retainer 132 may include tape that is disposed across the slit 116. In an example, the retainer 132 may include a sleeve (e.g., ring) that fits around the exterior surface 134. The sleeve may not be adhesively attached to the exterior surface 134 of the fluid impermeable barrier 102 and, instead, may rely on friction to maintain the sleeve on the exterior surface 134. In an example, the retainer 132 may include a Velcro strap that is attached to and/or extends around the exterior surface 134. In an example, the retainer 132 may include an elastic band, rope or other string, or any other suitable device.
The intermediate portion 108 is defined by at least the distal region 104, the proximal end region 106, and the lateral edges 118 of the intermediate portion 108. The shape of the intermediate portion 108 may depend whether the intermediate portion 108 is unflared or flared. For example, the intermediate portion 108 may exhibit a generally cylindrical shape when the intermediate portion 108 is unflared, a generally truncated cylindrical shape when the intermediate portion 108 is flared, and a generally flat shape when the intermediate portion 108 is completely flared. The intermediate portion 108 may exhibit other shapes, such as a generally rectangular shape, a generally semi-cylindrical shape, at least a portion of a generally parallelepiped shape, or any other suitable shape.
In an embodiment, the intermediate portion 108 is configured to attach the fluid collection assembly 100 to the patient 122. In such an embodiment, at least a portion of the intermediate portion 108 includes an adhesive (e.g., hydrogel) on an interior surface 137 of the fluid impermeable barrier 104 or the interior surface 136 of the porous material 120. The adhesive may be configured to attach the intermediate portion 108 to the shaft of the penis and/or the region about the penis 124 thereby securing the fluid collection assembly 100 to the patient. In an example, the portions of the fluid impermeable barrier 102 that form a portion of the interior surface 137 (e.g., the inwardly extending portion 146 and/or the chamber portion 148) may include the adhesive. In an example, at least a portion of the porous material 120 that forms the interior surface 136 includes the adhesive. In an example, only portions of the interior surface 136 adjacent or proximate to the proximal end region 106 and the lateral edges 118 include the adhesive. In such an example, the adhesive may be configured to form a seal that prevents the bodily fluids from flow out of the chamber 110.
Referring back to
The fluid impermeable barrier 102 at least partially defines the chamber 110. For example, the interior surface 137 of the fluid impermeable barrier 102 at least partially defines the perimeter of the chamber 110. The chamber 110 may at least temporarily retain fluids therein. In an example, portions of the chamber 110 may be substantially empty due to the varying sizes and rigidity of the male penis. However, in some examples, the outermost regions of the chamber 110 may include porous material 120 (e.g., one or more of the fluid permeable membrane 138 and fluid permeable support 140). For example, the porous material 120 may be bonded to at least a portion of the interior surface 137 of the fluid impermeable barrier 102. The porous material 120 may be positioned (e.g., at the distal end of the chamber 110) to blunt a stream of urine from the male urethra thereby limiting splashing and/or to direct the bodily fluids to a selected region of the chamber 110. Since the chamber 110 is substantially empty, the fluids are likely to pool at a gravimetrically low point of the chamber 110. The gravimetrically low point of the chamber 110 may be at an intersection of the skin of a patient and the fluid collection assembly 100, the distal region 104, or another suitable location depending on the orientation of the patient. It is noted that the varying length of the fluid collection assembly 100 may allow the penis to substantially completely occupy any portions of the chamber 110 that are not occupied by the porous material 120 or that forms the reservoir 152. Substantially completely occupying such portions of the chamber 110 may position the porous material 120 adjacent to the urethral opening, thereby causing the porous material 120 to receive substantially all of the bodily fluids discharged from the urethral opening and prevent the bodily fluids remaining in the unoccupied portions of the chamber 110.
The fluid impermeable barrier 102 may also define an opening 112 extending through the fluid impermeable barrier 102 that is configured to have the penis 124 positioned therethrough. The opening 112 may be defined by the portions of the fluid impermeable barrier 102 that form the proximal end region 106. For example, the opening 112 is formed in an extends through the fluid impermeable barrier 102, from the exterior surface 134 to the interior surface 137, thereby enabling the penis 124 and bodily fluids (e.g., when the penis 124 is buried) to enter the chamber 110. The opening 112 may also be formed in and extend through the porous material 120.
In some examples, the fluid impermeable barrier 102 may define the fluid outlet 114 that is sized to receive the conduit 142. The at least one conduit 142 may be disposed in the chamber 110 via the fluid outlet 114. The fluid outlet 114 may be sized and shaped to form an at least substantially fluid tight seal against the conduit 142 or the at least one tube thereby substantially preventing the bodily fluids from escaping the chamber 110.
The porous material 120 may include one or more of the fluid permeable membrane 138 or the fluid permeable support 140. One or more of the fluid permeable membrane 138 or the fluid permeable support 140 may be disposed between the fluid impermeable barrier 102 and a penis inserted into the chamber 110. The fluid permeable membrane 138 may be positioned between the fluid impermeable barrier 102 and a penis inserted into the chamber 110, such as between the fluid permeable support 140 and penis of a patient as shown. The fluid permeable support 140 may be positioned between the fluid permeable membrane 138 and the fluid impermeable barrier 102. The interior surface 137, optionally including the end of the chamber 110 substantially opposite the opening 112, may be covered with one or both the fluid permeable membrane 138 or the fluid permeable support 140. The fluid permeable support 140 or the fluid permeable membrane 138 may be affixed (e.g., adhered) to the fluid impermeable barrier 102. The fluid permeable support 140 or the fluid permeable membrane 138 may be affixed to each other.
The fluid collection assembly 100 includes assembly porous material 120 disposed in the chamber 110. The assembly porous material 120 may cover at least a portion (e.g., all) of the opening 112. The assembly porous material 120 may include a fluid permeable membrane 138 and a fluid permeable support 140. The assembly porous material 120 is exposed to the environment outside of the chamber 110 through the opening 112. In an embodiment, the assembly porous material 120 may be configured to wick any bodily fluids away from the opening 112, thereby preventing the bodily fluids from escaping the chamber 110. The permeable properties referred to herein may be wicking, capillary action, diffusion, or other similar properties or processes, and are referred to herein as “permeable” and/or “wicking.” Such “wicking” and/or “permeable” properties may not include absorption of the bodily fluids into at least a portion of the wicking material, such as not include adsorption of the bodily fluids into the fluid permeable support 140. Put another way, substantially no absorption or solubility of the bodily fluids into the material may take place after the material is exposed to the bodily fluids and removed from the bodily fluids for a time. While no absorption or solubility is desired, the term “substantially no absorption” may allow for nominal amounts of absorption and/or solubility of the bodily fluids into the wicking material (e.g., absorbency), such as less than about 30 wt % of the dry weight of the wicking material, less than about 20 wt %, less than about 10 wt %, less than about 7 wt %, less than about 5 wt %, less than about 3 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt % of the dry weight of the wicking material. The porous material may also wick the bodily fluids generally towards an interior of the chamber 110, as discussed in more detail below. In an embodiment, the assembly porous material 120 may include at least one absorbent or adsorbent material.
The fluid permeable membrane 138 may be composed to wick the bodily fluids away from the opening 112, thereby preventing the bodily fluids from escaping the chamber 110. The fluid permeable membrane 138 may include any material that may wick the bodily fluids. For example, the fluid permeable membrane 138 may include fabric, such as a gauze (e.g., a silk, linen, or cotton gauze), another soft fabric, or another smooth fabric. Forming the fluid permeable membrane 138 from gauze, paper, soft fabric, and/or smooth fabric may reduce chaffing caused by the fluid collection assembly 100. In an embodiment, the fluid permeable membrane 138 may become quickly saturated with the bodily fluids after the porous material 120 received the bodily fluids from the penis. The fluid permeable membrane 138 may become substantially impermeable to gases when the fluid permeable membrane 138 becomes saturated with the bodily fluids thereby preventing or at least minimizing loss of a vacuum through the fluid permeable membrane 138. Preventing or minimizing the loss of the vacuum through the fluid permeable membrane 138 may increase the quantity of and rate at which the bodily fluids are removed from the chamber 110.
The fluid collection assembly 100 may include the fluid permeable support 140 disposed in the chamber 110. The fluid permeable support 140 is configured to support the fluid permeable membrane 138 since the fluid permeable membrane 138 may be formed from a relatively foldable, flimsy, or otherwise easily deformable material. For example, the fluid permeable support 140 may be positioned such that the fluid permeable membrane 138 is disposed between the fluid permeable support 140 and the fluid impermeable barrier 102. As such, the fluid permeable support 140 may support and maintain the position of the fluid permeable membrane 138. The fluid permeable support 140 may include any material that may wick or be permeable to the bodily fluids, such as any of the fluid permeable membrane materials disclosed herein above. For example, the fluid permeable membrane material(s) may be utilized in a more dense or rigid form than in the fluid permeable membrane 138 when used as the fluid permeable support 140. The fluid permeable support 140 may be formed from any fluid permeable material that is less deformable than the fluid permeable membrane 138. For example, the fluid permeable support 140 may include a porous polymer (e.g., nylon, polyester, polyurethane, polyethylene, polypropylene, etc.) structure or an open cell foam, such as spun nylon fiber. In some examples, the fluid permeable support 140 may be formed from a natural material, such as cotton, wool, silk, or combinations thereof. In an example, the fluid permeable support 140 may include a nonwoven material or a woven material (e.g., spun nylon fibers). In some examples, the fluid permeable support 140 may be formed from fabric, felt, gauze, or combinations thereof.
In an embodiment, the fluid permeable support 140 may be hydrophobic. The fluid permeable support 140 may be hydrophobic when the fluid permeable support 140 exhibits a contact angle with water (a major constituent of bodily fluids) that is greater than about 90°, such as in ranges of about 90° to about 120°, about 105° to about 135°, about 120° to about 150°, about 135° to about 175°, or about 150° to about 180°. The hydrophobicity of the fluid permeable support 140 may limit absorption, adsorption, and solubility of the bodily fluids in the fluid permeable support 140 thereby decreasing the amount of bodily fluids held in the assembly porous material 120. In an embodiment, the fluid permeable membrane 138 is hydrophobic or hydrophilic. In an embodiment, the fluid permeable support 140 is more hydrophobic (e.g., exhibits a larger contact angle with water) than the fluid permeable membrane 138. The lower hydrophobicity of the fluid permeable membrane 138 may help the assembly porous material 120 receive the bodily fluids from the urethral opening while the hydrophobicity of the fluid permeable support 140 limits the bodily fluids that are retained in the assembly porous material 120.
In some examples, the fluid permeable membrane 138 may be optional. For example, the porous material 120 may include only the fluid permeable support 140. In some examples, the fluid permeable support 140 may be optionally omitted from the fluid collection assembly 100. For example, the porous material 120 may only include the fluid permeable membrane 138. In some examples, the porous material 120 may include one or more additional layers in addition to or instead of at least one of the fluid permeable membrane 138 or the fluid permeable support 140.
In an embodiment, at least a portion of the porous material 120 at or near the proximal end region 106 may exhibit a tube-like structure (not shown) extending circumferentially about the proximal end region between the LAF. The tube-like structure of the porous material may include the fluid permeable membrane 138 rolled up into a generally curved cylindrical shape that may or may not define a channel. The fluid permeable support 140 may surround the fluid permeable membrane 138. Examples of a porous material 120 that exhibits a tube-like structure is disclosed in U.S. Pat. No. 10,376,406 filed on Jul. 27, 2016, the disclosure of which is disclosed herein, in its entirety, by this reference.
In an embodiment, the porous material 120 may be adjacent to substantially all of the interior surface 137 of the fluid impermeable barrier 102 such that there are substantially no gaps between the porous material 120 and the fluid impermeable barrier 102 ignoring the inherent porosity of the porous material 120. In an embodiment, the porous material 120 may not be adjacent to one or more portions of the interior surface 137 of the fluid impermeable barrier 102. In such an embodiment, the chamber 110 includes at least one reservoir 152 that is a substantially unoccupied portion of the chamber 110 that is between the fluid impermeable barrier 102 and the porous material 120. The bodily fluids that are in the chamber 110 may flow through the porous material 120 to the reservoir 152. The reservoir 152 may retain the bodily fluids therein until the bodily fluids are removed from the chamber 110. The reservoir 152 is depicted in the distal region 104 since the fluid outlet 114 is at or near the distal region 104. However, the reservoir 152 may be located in any portion of the chamber 110 between the fluid impermeable barrier 102 and the porous material 120, such as the proximal end region 106. The reservoir 152 may be located adjacent or proximate to the fluid outlet 114 or a gravimetrically low point of the fluid collection assembly 100 when the fluid collection assembly 100 is worn.
The fluid impermeable barrier 102 and the porous material 120 may be configured to prevent leaks from the chamber 110. In an example, the fluid impermeable barrier 102 may be configured such that the fluid impermeable barrier 102 that defines at least a portion of the lateral edges 118 contact each other when the when the slit 116 is closed (e.g., the lateral edges 118 contact each other or a portion of the intermediate portion 108 overlaps another portion of the intermediate portion 108). The fluid impermeable barrier 102 contacting itself prevents the formation of gaps through which the bodily fluids may leak and vacuum may be lost. In an example, as previously discussed, the fluid permeable membrane 138 may be configured to be substantially impermeable to gas when the fluid permeable membrane 138 becomes saturated with the bodily fluids. The saturated fluid permeable membrane 138 decreases vacuum loss which pulls the bodily fluids towards the fluid outlet 114, inhibits movement of the bodily fluids towards the slit 116 and the opening 112, and increases the quantity and rate at which the bodily fluids are removed from the chamber 110.
In an example, the fluid impermeable barrier 102 at least partially covers (e.g., extends around at least a portion of) one or more edges 144 of the porous material 120. In such an example, the fluid impermeable barrier 102 may include at least one inwardly extending portion 146 extending inwardly from a portion of the fluid impermeable barrier 102 that extends generally parallel to the porous material 120. The fluid impermeable barrier 102 may optionally include includes at least one chamber portion 148 extending from the inwardly extending portion 146 into the chamber 110. The inwardly extending portion 146 and/or the chamber portion 148 of the fluid impermeable barrier 102 form at least one of at least a portion of the proximal end region 106 (e.g., define a portion of the opening 112) or at least a portion of the lateral edges 118. The inwardly extending portion may prevent or at least inhibit bodily fluids from flowing out of the porous material 120 through the edges 144 thereof. The inwardly extending portion may also prevent or at least inhibit the vacuum being lost through the edges 144 of the porous material 120. The inwardly extending portion 146 and the chamber portion 148 of the fluid impermeable barrier 102 may also form a channel 150 that may store bodily fluids that reach the proximal end region 106 or the lateral edges 118. The bodily fluids stored in the channel 150 may be pulled from the channel 150 as bodily fluids are removed from the chamber 110 due to hydrogen bonding. The inwardly extending portion 146 and/or the chamber portion 148 may also increase contact between the fluid impermeable barrier 102 when the slit 116 is closed and/or a portion of the intermediate portion 108 overlaps another portion of the intermediate portion 108. The increased contact between the fluid impermeable barrier 102 reduces the likelihood that the bodily fluids leak through the slit 116.
The conduit 142 may be used to remove the bodily fluids from the chamber 110. The conduit 142 (e.g., a tube) includes an inlet 154 and an outlet (not shown) positioned downstream from the inlet 154. The outlet may be operably coupled to a vacuum source, such as a vacuum pump for withdrawing fluid from the chamber 110 through the conduit 142. For example, the conduit 142 may extend into the fluid impermeable barrier 102 from to the fluid outlet 114 to a point proximate to the reservoir 152 therein such that the inlet 154 is in fluid communication with the reservoir 152. The conduit 142 fluidly couples the chamber 110 with the fluid storage container (not shown) or the vacuum source (not shown).
The conduit 142 may include a flexible material such as plastic tubing (e.g., medical tubing). Such plastic tubing may include a thermoplastic elastomer, polyvinyl chloride, ethylene vinyl acetate, polytetrafluoroethylene, etc., tubing. In some examples, the conduit 142 may include silicon or latex. In some examples, the conduit 142 may include one or more portions that are resilient, such as to by having one or more of a diameter or wall thickness that allows the conduit to be flexible.
As described in more detail below, the conduit 142 is configured to be coupled to, and at least partially extend between, one or more of the fluid storage container (not shown) and the vacuum source (not shown). In an example, the conduit 142 is configured to be directly connected to the vacuum source (not shown). In such an example, the conduit 142 may extend from the fluid impermeable barrier 102 by at least one foot, at least two feet, at least three feet, at least six feet, or at least eight feet. In another example, the conduit 142 is configured to be indirectly connected to at least one of the fluid storage container (not shown) and the vacuum source (not shown). In some examples, the conduit is secured to a patient's skin with a catheter securement device, such as a STATLOCK® catheter securement device available from C. R. Bard, Inc., including but not limited to those disclosed in U.S. Pat. Nos. 6,117,163; 6,123,398; and 8,211,063, the disclosures of which are all incorporated herein by reference in their entirety.
The inlet 154 and the outlet are configured to fluidly couple (e.g., directly or indirectly) the vacuum source (not shown) to the chamber 110 (e.g., the reservoir 152). As the vacuum source (
The slit 116 illustrated in
The LAF of the fluid collection assembly 200 includes a plurality of perforations 216 that extend through at least a portion of the fluid impermeable barrier 202. The perforations 216 may be arranged in a path, such as a substantially straight path. The plurality of perforations 216 may extend from the proximal end region 206 to the distal region 204. The perforations 216 weaken the fluid impermeable barrier 202 such that the fluid impermeable barrier 202 is configured to tear along the path. Tearing the fluid impermeable barrier 202 along the path formed by the perforations 216 forms a slit that functions substantially similar to the slit 116 illustrated in
The slit formed using the perforations 216 does not need to extend the whole length of the path formed by the perforations 216. Instead, the slit formed using the perforations 216 may only extend a portion of the length of the path depending on the size of the penis that the fluid collection assembly 200 is used with. For example, the slit formed using the perforations 216 may only extend about greater than 0% to about 20%, about 10% to about 30%, about 20% to about 40%, about 30% to about 50%, about 40% to about 60%, about 50% to about 70%, about 60% to about 80%, about 70% to about 90%, or about 80% to about 100% the length of the path formed by the perforations 216. The percentage of the length of the path that the slit extends may be selected based on the length of the path, the maximum length of the fluid collection assembly 100, the final length of the fluid collection assembly 200, and the length of the penis. Only tearing the a portion of the path formed by the protrusion 216 allows the slit to exhibit a length that was specifically selected for a specific sized penis. In other words, the length of the slit formed from the perforations may be selected to only be as large as necessary. The selected length of the slit formed from the perforations 216 may exhibit a length that is less than the slit 116 illustrated in
Referring to
The LAF may include features other than a slit or a plurality of perforations. In an example, the LAF may include a portion of the fluid collection assembly that is weakened, such as by selectively thinning a portion of one or more components of the fluid collection assembly or forming a portion of one or more components of the fluid collection assembly from a weaker, more easily tear-able material. The weakened portions may facilitate tearing of a portion of the fluid collection assembly similar to the plurality of perforations. In an example, the LAF may include a flexible material that extends across a recess that extends through the fluid impermeable barrier and porous material. The flexible material and the recess allows the intermediate portion of the fluid collection assembly to flare but the flexible material may prevent or at least inhibit flow of bodily fluids through the recess. In an example, the LAF may include a combination of any of the LAFs disclosed herein, such as a slit and a plurality of protrusions extending from the slit towards the distal region.
Referring back to
As such, the fluid collection assemblies disclosed herein may include positioning the inlet of the conduit at or near the expected gravimetric low point of the chamber even when the expected gravimetric low point of the chamber is not at or near the distal region. In an embodiment, the fluid outlet of the fluid collection assembly may be at or near the gravimetric low point of the chamber and spaced from the distal region. In an embodiment, as illustrated in
In an embodiment, the gravimetric low point of the chamber 310 is expected to be at a location that is spaced from the fluid outlet 314. For example, the fluid outlet 314 may be located at or near the distal region 304 of the fluid collection assembly 300 while the gravimetric low point of the chamber 310 is expected to be at or near the proximal end region 306. It is noted that the fluid outlet 314 may be located at a location other than the distal region 304 (e.g., the intermediate portion 308 and/or near the proximal end region 306). It is also noted that the gravimetric low point of the chamber 310 may be at a location other than near the proximal end region 306 depending on at least one of the position of the patient (e.g., standing, sitting, or lying down) and/or the direction that the penis extends when the penis is erect or flaccid.
The conduit 342 may extend from the fluid outlet 314 to the expected gravimetric low point of the chamber 310 such that the inlet 354 of the conduit 342 is at or near the expected gravimetric low point. For example, in the illustrated embodiment, the conduit 342 may extend from the fluid outlet 314, at least one of between the fluid impermeable barrier 302 and the porous material 320, through the porous material 320 (e.g., through a bore formed in the porous material 320), or in an unoccupied spaced defined partially by the porous material 320 that also receives the penis (not shown). Positioning the inlet 354 of the conduit 342 at or near the expected gravimetric low point of the chamber 310 may facilitate removal of the bodily fluids from the chamber 310 since at least some of the bodily fluids may flow towards the gravimetric low point of the chamber 310.
In an embodiment, the chamber 310 may include a substantially unoccupied space at or near the proximal end region 306 or any other location that may be expected to be the gravimetric low point of the chamber 310. The substantially unoccupied space may be a reservoir 352 that is configured to temporarily store the bodily fluids therein.
In an embodiment, the conduit of any of the fluid collection assemblies disclosed herein may define a plurality of inlets thereby allowing the conduit to receive bodily fluids from a variety of locations in the chamber. In an embodiment, the conduit of any of the fluid collection assemblies disclosed herein may include a plurality of conduits and an inlet of at least one of the plurality of conduits is positioned in a location that is different than an inlet of at least one other one of the plurality of conduits thereby allowing the conduits to receive bodily fluids from a variety of locations in the chamber.
The fluid collection assemblies illustrated in
The fluid collection assembly 400 includes two intermediate portions 408 each extending from the distal region 404 to the proximal end regions 406. The two intermediate portions 408 are separated from each other by two LAFs 416. In the illustrated embodiment, the two intermediate portions 408 may be generally aligned linearly and/or may extend generally parallel to each other as the two intermediate portions 408 extend from the distal region 404. However, the two intermediate portions 408 may also extend from the distal region 404 while not being at least one of generally aligned linearly with each other or generally parallel to each other.
The intermediate portions 408 may be the same or substantially similar to any of the intermediate portions disclosed herein. For example, the intermediate portions 408 may include a fluid impermeable barrier 402 and at least one porous material 420 disposed adjacent to at least a portion of the fluid impermeable barrier 402 of each of the intermediate portions 408. The intermediate portions 408 may also exhibit any shape disclosed herein. For example, the intermediate portions 408 may exhibit a generally rectangular shape, a generally semi-cylindrical shape, a generally parallelepiped shape, or any other suitable shape.
In an embodiment, the two intermediate portions 408 are substantially the same. For example, the two intermediate portions 408 may exhibit the same size, the same shape, etc. In an embodiment, the two intermediate portions 408 may be different from each other in one or more aspects. For example, the intermediate portions 408 may exhibit different sizes, different shapes, one of the intermediate portions 408 may include a porous material 420 that is different than a porous material 420 of the other intermediate portion 408, one intermediate portion 408 may include a reservoir and/or a conduit extending therethrough while the other intermediate portion 408 does not, one intermediate portion 408 may include the fluid outlet 414, etc.
In an embodiment, the flared portions 426 of the intermediate portions 408 may be flared outwardly until each of the flared portions 426 exhibits a shape that generally corresponds to the shape of the region about the penis that the flared portions 426 contact. The portions of the body that the flared portions 426 correspond to may depend on the orientation (e.g., rotation) of the fluid collection assembly 400 exhibit relative to the patient. In an example, the flared portions 426 may be flared until at least a portion of the flared portions 426 exhibit a shape that generally corresponds to the shape of the thighs of the patient. In an example, the flared portions 426 may be flared until at least a portion of the flared portion 426 of one of the intermediate portions 408 exhibit a shape that generally corresponds to the shape of at least a portion of the testicles of the patient while the flared portion 426 of the other intermediate portions 408 exhibits a shape that generally corresponds to the shape of the mons pubis. In an embodiment, the flared portions 426 may be flared such that the flared portions 426 do not exhibit a shape that corresponds to the shape of the region about the penis. For example, the flared portions 426 may be folded upwardly such that at least a portion of the fluid impermeable barrier 402 of the flared portions 426 is adjacent to the fluid impermeable barrier 402 of at least a portion of the rest of the fluid collection assembly 400.
As previously discussed, the fluid collection assembly 400 includes two intermediate portions. However, any of the fluid collection assemblies disclosed herein may include more than two intermediate portions, such as three intermediate portions as illustrated in
As previously discussed, the fluid collection assembly 500 includes three intermediate portions 508. The three intermediate portions 508 allows the fluid collection assembly 500 to be attached to more regions of the body of the patient that is using the fluid collection assembly 500 than if the fluid collection assembly 500 only included one or two intermediate portions. In an example, the three intermediate portions 308 allows the fluid collection assembly 500 to be attached to the two thighs and the mons pubis of the patient. Allowing the fluid collection assembly 500 to be attached to more portions of the bodily causes the fluid collection assembly 500 to pull less on each portion of the patient thereby increasing patient comfort In an example, the three intermediate portions 508 allows two of the intermediate portions 508 to be attached above the penis (i.e., in a region generally between the penis and head of the patient) or to the side of the penis while the remaining intermediate portion 508 may be attached below the penis (i.e., in a region generally between the penis and the feet of the patient). In an example, the three intermediate portions 508 allows two of the intermediate portions 508 to be attached below or to the sides of the penis while the remaining intermediate portion 508 may be attached above the penis. In an embodiment, the three intermediate portions 508 may minimize pivoting and increase the likelihood that the fluid collection assembly 500 stays attached to the patient than if the fluid collection assembly 500 included fewer intermediate portions.
The three intermediate portions 508 may allow the fluid collection assembly 500 to be attached to the patient without attaching one or more of the intermediate portions 508 to sensitive portions of the patient (e.g., testicles) compared to a fluid collection assembly that includes two or fewer intermediate portions. In an example, the intermediate portions 508 may be attached to the mons pubis without also attaching the intermediate portions 508 to the testicles whereas attaching one of the intermediate portions 408 of the fluid collection assembly 400 illustrated in
It is noted that generally, increasing the number of intermediate portions increases the comfort of using the fluid collection assembly by increasing the number of locations to which the intermediate portions may be attached while also avoiding more sensitive portions of the patient.
Referring to
The intermediate portions of any of the fluid collection assemblies disclosed herein may have non-equidistantly spaced intermediate portions (e.g., an angle between two adjacent lateral edges of a first set of two different intermediate portions is different than an angle between two other adjacent lateral edges of a second set of two different intermediate portions). For example,
The angle θ and the angle α may be selected such that the intermediate portions 508′ are attached to selected portions of the body and/or avoid certain portions of the body. For example, the angle θ may be selected such that the intermediate portions 508′ that the angle θ is measured between avoids the testicles. For instance, the angle θ may be selected to be about 120° to about 200° (e.g., about 180°) thereby allowing the corresponding set of adjacent intermediate portions 508′ are attached to the thighs instead of the testicles. The angle α may be selected such that one of the intermediate portions 508′ that the angle α is measured between contacts the mons pubis or another location other than the testicles. As such, the angle θ and the angle α are selected to avoid attaching or contacting one of the intermediate portions 508′ against the testicles.
In some embodiments, the intermediate portions of any of the fluid collection assemblies disclosed herein may overlap. For example,
As previously discussed, the fluid collection assembly 600 includes a plurality of intermediate portions 608 and at least a portion of at least some of the plurality of intermediate portions 608 overlap with each other. The intermediate portions 608 overlap when one intermediate portion 608 covers a portion of another intermediate portion 608 (e.g., an adjacent intermediate portion 608) when the intermediate portions 608 are completely flared. The overlapping intermediate portion 608 generally covers a portion of the adjacent intermediate portion 608 that is adjacent to the distal region 604.
The overlapping of the intermediate portions 608 prevents or at least inhibits bodily fluids from leaking from the chamber (not shown) of the fluid collection assembly 600. For example, one of the more likely locations of the fluid collection assembly 600 that the bodily fluids may leak from is through the LAF adjacent to the distal region 604. In fluid collection assemblies that do not include overlapping intermediate portions, any bodily fluids that flow around the lateral edge of an intermediate portion adjacent to the distal region may be able to leak from the such a fluid collection assembly. However, in the fluid collection assembly 600 illustrated in
In an embodiment, all of the intermediate portions 608 are partially overlapped by another intermediate portion 608 and, by extension, all of the intermediate portions 608 partially overlap another intermediate portion 608. In an embodiment, at least one of the intermediate portions 608 is overlapped by two intermediate portions adjacent intermediate portion 608. In an embodiment, at least one of the intermediate portion 608 is not overlapped and/or does not overlap another intermediate portion 608.
The fluid collection assemblies illustrated in
The fluid collection assemblies illustrated in
The fluid collection assembly 700 includes a first intermediate portion 708a and a second intermediate portion 708b. The first intermediate portion 708a extends a first distance from the distal region 704 and the second intermediate portion 708b extends a second distance from the distal region 704, wherein the second distance is greater than the first distance. In other words, the first intermediate portion 708a exhibits a length that is less than a length of the second intermediate portion 708b. As will be discussed in more detail with regards to
The proximal end region 706 formed by the first intermediate portion 708a or a portion of the first intermediate portion 708a adjacent to the proximal end region 706 is configured to abut or at least partially surround the penis 724 (shown in
In an embodiment, the first intermediate portion 708a may define a cutout 756. The cutout 756 may extend inwardly from (as shown) from the proximal end region 706 or may be a hole proximate the proximal end region 706 that is completely surrounded by the first intermediate portion 708. The cutout 756 is configured to receive the penis 724 such that the first intermediate portion 708a partially surrounds (when the cutout 756 extends inwardly from the proximal end region 706) or completely surrounds (when the cutout 756 is a hole) the penis 724. The cutout 756 allows the first intermediate portion 708a to be adjacent to or abut more of the penis 724 than if the first intermediate portion 708a did not include the cutout 756. As such, the cutout 756 allows the first intermediate portion 708a to receive or at least maintain in the chamber 710 more of the bodily fluids that if the first intermediate portion 708a did not include the cutout 756.
The fluid collection assemblies illustrated in
As previously discussed, the distal region 804 of the fluid collection assembly 800 is not a sump. Such a distal region 804 may allow the fluid collection assembly 800 to lie flat on a surface or otherwise conform to the shape of a surface. The ability of the fluid collection assembly 800 to lie flat on a surface or otherwise conform to the shape of the surface may allow the fluid collection assembly 800 to be more effectively used with a buried penis. For example, the distal region 804 of the fluid collection assembly 800 may lie flat across the buried penis thereby allowing the urethral opening to be positioned closer to the fluid outlet 814 than if the distal region 804 included a sump. It is noted that a fluid collection assembly may still be used with a buried penis if the distal region thereof is a sump but that the sump may increase the distance between the urethral opening of the buried penis and the fluid outlet.
The at least one intermediate portion 808 of the fluid collection assembly 800 allows the fluid collection assembly 800 to be used with non-buried penises. For example, at least a portion of the lateral edges 818 may be positioned together thereby allowing the intermediate portion 808 in conjunction with the distal region 804 to form a sump-like shape. The non-buried penis may be disposed in the sump-like shape.
It is noted that the fluid outlet 814 may extend outwardly from the rest of the fluid collection assembly 800 when the fluid collection assembly 800 lies flat. Extending the fluid outlet 814 outwardly from the rest of the fluid collection assembly 800 may facilitate attaching the conduit 842 thereto. However, the fluid outlet 814 is too small to form a sump in which the glans of the penis may be positioned therein. Thus, the fluid collection assembly 800 may include a distal region 804 that is not a sump but also include a fluid outlet 814 extending outwardly from the rest of the fluid collection assembly 800.
The suction force may be applied to the outlet of the conduit 942 by the vacuum source 909 either directly or indirectly. The suction force may be applied indirectly via the fluid storage container 907. For example, the outlet of the conduit 942 may be disposed within the fluid storage container 907 and an additional conduit 942 may extend from the fluid storage container 907 to the vacuum source 909. Accordingly, the vacuum source 909 may apply suction to the fluid collection assembly 900 via the fluid storage container 907. The suction force may be applied directly via the vacuum source 909. For example, the outlet of the conduit 942 may be disposed within the vacuum source 909. An additional conduit 942 may extend from the vacuum source 909 to a point outside of the fluid collection assembly 900, such as to the fluid storage container 907. In such examples, the vacuum source 909 may be disposed between the fluid collection assembly 900 and the fluid storage container 907.
The fluid storage container 907 is sized and shaped to retain the bodily fluids therein. The fluid storage container 907 may include a bag (e.g., drainage bag), a bottle or cup (e.g., collection jar), or any other enclosed container for storing bodily fluids such as urine. In some examples, the conduit 942 may extend from the fluid collection assembly 900 and attach to the fluid storage container 907 at a first point therein. An additional conduit 942 may attach to the fluid storage container 907 at a second point thereon and may extend and attach to the vacuum source 909. Accordingly, a vacuum (e.g., suction) may be drawn through fluid collection assembly 900 via the fluid storage container 907. Fluid, such as urine, may be drained from the fluid collection assembly 900 using the vacuum source 909.
The vacuum source 909 may include one or more of a manual vacuum pump, and electric vacuum pump, a diaphragm pump, a centrifugal pump, a displacement pump, a magnetically driven pump, a peristaltic pump, or any pump configured to produce a vacuum. The vacuum source 909 may provide a vacuum or suction to remove fluid from the fluid collection assembly 900. In some examples, the vacuum source 909 may be powered by one or more of a power cord (e.g., connected to a power socket), one or more batteries, or even manual power (e.g., a hand operated vacuum pump). In some examples, the vacuum source 909 may be sized and shaped to fit outside of, on, or within the fluid collection assembly 900. For example, the vacuum source 909 may include one or more miniaturized pumps or one or more micro pumps. The vacuum sources 909 disclosed herein may include one or more of a switch, a button, a plug, a remote, or any other device suitable to activate the vacuum source 909.
The fluid collection assemblies disclosed herein are discussed as being used with a penis. For example, the fluid collection assemblies are disclosed as being positioned on, around, or above a penis. However, it is noted that the fluid collection assemblies disclosed herein may collect bodily fluids from anatomy other than a penis. In an embodiment, the fluid collection assemblies disclosed herein may be positioned on, around, or above a female urethral opening (e.g., vaginal) thereby allowing the fluid collection assemblies to remove urine, blood, vagina discharge, or other relevant bodily fluids from the vagina. In an embodiment, the fluid collection assemblies disclosed herein may be positioned on, around, or above a wound thereby allowing the fluid collection assemblies to receive and remove blood, puss, serous fluid, or other relevant bodily fluids from the wound. In an embodiment, the fluid collection assemblies may be disposed on any other anatomical feature of a patient to remove moisture, oil, or other bodily fluids from the anatomical feature, such as a finger of a surgeon.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments are contemplated. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting.
Terms of degree (e.g., “about,” “substantially,” “generally,” etc.) indicate structurally or functionally insignificant variations. In an example, when the term of degree is included with a term indicating quantity, the term of degree is interpreted to mean±10%, ±5%, or ±2% of the term indicating quantity. In an example, when the term of degree is used to modify a shape, the term of degree indicates that the shape being modified by the term of degree has the appearance of the disclosed shape. For instance, the term of degree may be used to indicate that the shape may have rounded corners instead of sharp corners, curved edges instead of straight edges, one or more perforations extending therefrom, is oblong, is the same as the disclosed shape, etc.
| Number | Name | Date | Kind |
|---|---|---|---|
| 737443 | Mooers | Aug 1903 | A |
| 1032841 | Koenig | Jul 1912 | A |
| 1178644 | Johnson | Apr 1916 | A |
| 1387726 | Karge | Aug 1921 | A |
| 1742080 | Jones | Dec 1929 | A |
| 1979899 | Obrien et al. | Nov 1934 | A |
| 2241010 | Chipley | May 1941 | A |
| 2262772 | Peder | Nov 1941 | A |
| 2326881 | Packer | Aug 1943 | A |
| 2379346 | Farrell | Jun 1945 | A |
| 2485555 | Bester | Oct 1949 | A |
| 2571357 | Charles | Oct 1951 | A |
| 2613670 | Edward | Oct 1952 | A |
| 2616426 | Adele | Nov 1952 | A |
| 2644234 | Earl | Jul 1953 | A |
| 2648335 | Chambers | Aug 1953 | A |
| 2859786 | Tupper | Nov 1958 | A |
| 2944551 | Carl | Jul 1960 | A |
| 2968046 | Duke | Jan 1961 | A |
| 2971512 | Reinhardt | Feb 1961 | A |
| 3032038 | Swinn | May 1962 | A |
| 3077883 | Hill | Feb 1963 | A |
| 3087938 | Hans et al. | Apr 1963 | A |
| 3169528 | Knox et al. | Feb 1965 | A |
| 3171506 | Therkel | Mar 1965 | A |
| 3194238 | Breece | Jul 1965 | A |
| 3198994 | Hildebrandt et al. | Aug 1965 | A |
| 3221742 | Egon | Dec 1965 | A |
| 3312221 | Overment | Apr 1967 | A |
| 3312981 | McGuire et al. | Apr 1967 | A |
| 3349768 | Keane | Oct 1967 | A |
| 3362590 | Gene | Jan 1968 | A |
| 3366116 | Huck | Jan 1968 | A |
| 3398848 | Donovan | Aug 1968 | A |
| 3400717 | Bruce et al. | Sep 1968 | A |
| 3406688 | Bruce | Oct 1968 | A |
| 3424163 | Gravdahl | Jan 1969 | A |
| 3425471 | Yates | Feb 1969 | A |
| 3511241 | Lee | May 1970 | A |
| 3512185 | Ellis | May 1970 | A |
| 3520300 | Flower | Jul 1970 | A |
| 3528423 | Lee | Sep 1970 | A |
| 3613123 | Langstrom | Oct 1971 | A |
| 3648700 | Warner | Mar 1972 | A |
| 3651810 | Ormerod | Mar 1972 | A |
| 3661155 | Lindan | May 1972 | A |
| 3683918 | Pizzella | Aug 1972 | A |
| 3699815 | Holbrook | Oct 1972 | A |
| 3726277 | Hirschman | Apr 1973 | A |
| 3742952 | Magers et al. | Jul 1973 | A |
| 3757355 | Allen et al. | Sep 1973 | A |
| 3788324 | Lim | Jan 1974 | A |
| 3843016 | Bornhorst et al. | Oct 1974 | A |
| 3863638 | Rogers et al. | Feb 1975 | A |
| 3863798 | Kurihara et al. | Feb 1975 | A |
| 3864759 | Horiuchi | Feb 1975 | A |
| 3865109 | Elmore et al. | Feb 1975 | A |
| 3881486 | Fenton | May 1975 | A |
| 3881489 | Hartwell | May 1975 | A |
| 3915189 | Holbrook et al. | Oct 1975 | A |
| 3998228 | Poidomani | Dec 1976 | A |
| 3999550 | Martin | Dec 1976 | A |
| 4015604 | Csillag | Apr 1977 | A |
| 4020843 | Kanall | May 1977 | A |
| 4022213 | Stein | May 1977 | A |
| 4027776 | Douglas | Jun 1977 | A |
| 4064962 | Hunt | Dec 1977 | A |
| 4116197 | Bermingham | Sep 1978 | A |
| 4180178 | Turner | Dec 1979 | A |
| 4187953 | Turner | Feb 1980 | A |
| 4194508 | Anderson | Mar 1980 | A |
| 4200102 | Duhamel et al. | Apr 1980 | A |
| 4202058 | Anderson | May 1980 | A |
| 4203503 | Bertotti et al. | May 1980 | A |
| 4209076 | Bertotti et al. | Jun 1980 | A |
| 4223677 | Anderson | Sep 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4233978 | Hickey | Nov 1980 | A |
| 4246901 | Frosch et al. | Jan 1981 | A |
| 4253542 | Ruspa et al. | Mar 1981 | A |
| 4257418 | Hessner | Mar 1981 | A |
| 4270539 | Frosch et al. | Jun 1981 | A |
| 4281655 | Terauchi | Aug 1981 | A |
| 4292916 | Bradley et al. | Oct 1981 | A |
| 4330239 | Gannaway | May 1982 | A |
| 4352356 | Tong | Oct 1982 | A |
| 4360933 | Kimura et al. | Nov 1982 | A |
| 4365363 | Windauer | Dec 1982 | A |
| 4375841 | Vielbig | Mar 1983 | A |
| 4387726 | Denard | Jun 1983 | A |
| 4403991 | Hill | Sep 1983 | A |
| 4425130 | Desmarais | Jan 1984 | A |
| 4446986 | Bowen et al. | May 1984 | A |
| 4453938 | Brendling | Jun 1984 | A |
| 4457314 | Knowles | Jul 1984 | A |
| 4476879 | Jackson | Oct 1984 | A |
| 4526688 | Schmidt et al. | Jul 1985 | A |
| 4528703 | Kraus | Jul 1985 | A |
| D280438 | Wendt | Sep 1985 | S |
| 4551141 | Mcneil | Nov 1985 | A |
| 4553968 | Komis | Nov 1985 | A |
| 4581026 | Schneider | Apr 1986 | A |
| 4589516 | Inoue et al. | May 1986 | A |
| 4601716 | Smith | Jul 1986 | A |
| 4610675 | Triunfol | Sep 1986 | A |
| 4620333 | Ritter | Nov 1986 | A |
| 4626250 | Schneider | Dec 1986 | A |
| 4627846 | Ternstroem | Dec 1986 | A |
| 4631061 | Martin | Dec 1986 | A |
| 4650477 | Johnson | Mar 1987 | A |
| 4655754 | Richmond et al. | Apr 1987 | A |
| 4656675 | Fajnsztajn | Apr 1987 | A |
| 4681570 | Dalton | Jul 1987 | A |
| 4681577 | Stern et al. | Jul 1987 | A |
| 4692160 | Nussbaumer | Sep 1987 | A |
| 4707864 | Ikematsu et al. | Nov 1987 | A |
| 4713065 | Koot | Dec 1987 | A |
| 4713066 | Komis | Dec 1987 | A |
| 4723953 | Pratt et al. | Feb 1988 | A |
| 4735841 | Sourdet | Apr 1988 | A |
| 4743236 | Manschot | May 1988 | A |
| 4747166 | Kuntz | May 1988 | A |
| 4752944 | Conrads et al. | Jun 1988 | A |
| 4769215 | Ehrenkranz | Sep 1988 | A |
| 4771484 | Mozell | Sep 1988 | A |
| 4772280 | Rooyakkers | Sep 1988 | A |
| 4784654 | Beecher | Nov 1988 | A |
| 4790830 | Hamacher | Dec 1988 | A |
| 4790835 | Elias | Dec 1988 | A |
| 4791686 | Taniguchi et al. | Dec 1988 | A |
| 4795449 | Schneider et al. | Jan 1989 | A |
| 4798603 | Meyer et al. | Jan 1989 | A |
| 4799928 | Crowley | Jan 1989 | A |
| 4804377 | Hanifl et al. | Feb 1989 | A |
| 4812053 | Bhattacharjee | Mar 1989 | A |
| 4813943 | Smith | Mar 1989 | A |
| 4820297 | Kaufman et al. | Apr 1989 | A |
| 4846818 | Keldahl et al. | Jul 1989 | A |
| 4846909 | Klug et al. | Jul 1989 | A |
| 4865595 | Heyden | Sep 1989 | A |
| 4880417 | Yabrov et al. | Nov 1989 | A |
| 4882794 | Stewart | Nov 1989 | A |
| 4883465 | Brennan | Nov 1989 | A |
| 4886498 | Newton | Dec 1989 | A |
| 4886508 | Washington | Dec 1989 | A |
| 4886509 | Mattsson | Dec 1989 | A |
| 4889532 | Metz et al. | Dec 1989 | A |
| 4889533 | Beecher | Dec 1989 | A |
| 4890691 | Ching-Ho | Jan 1990 | A |
| 4903254 | Haas | Feb 1990 | A |
| 4904248 | Vaillancourt | Feb 1990 | A |
| 4905692 | More | Mar 1990 | A |
| 4936838 | Cross et al. | Jun 1990 | A |
| 4955922 | Terauchi | Sep 1990 | A |
| 4957487 | Gerow | Sep 1990 | A |
| 4965460 | Tanaka et al. | Oct 1990 | A |
| 4986823 | Anderson et al. | Jan 1991 | A |
| 4987849 | Sherman | Jan 1991 | A |
| 5002541 | Conkling et al. | Mar 1991 | A |
| 5004463 | Nigay | Apr 1991 | A |
| 5031248 | Kemper | Jul 1991 | A |
| 5045077 | Blake | Sep 1991 | A |
| 5045283 | Patel | Sep 1991 | A |
| 5049144 | Payton | Sep 1991 | A |
| 5053339 | Patel | Oct 1991 | A |
| 5057092 | Webster | Oct 1991 | A |
| 5058088 | Haas et al. | Oct 1991 | A |
| 5071347 | McGuire | Dec 1991 | A |
| 5078707 | Peter Klug | Jan 1992 | A |
| 5084037 | Barnett | Jan 1992 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5112324 | Wallace | May 1992 | A |
| 5147301 | Ruvio | Sep 1992 | A |
| 5176667 | Debring | Jan 1993 | A |
| 5195997 | Carns | Mar 1993 | A |
| 5196654 | Diflora et al. | Mar 1993 | A |
| 5203699 | McGuire | Apr 1993 | A |
| 5244458 | Takasu | Sep 1993 | A |
| 5246454 | Peterson | Sep 1993 | A |
| 5267988 | Farkas | Dec 1993 | A |
| 5275307 | Freese | Jan 1994 | A |
| 5282795 | Finney | Feb 1994 | A |
| 5294983 | Ersoz et al. | Mar 1994 | A |
| 5295983 | Kubo | Mar 1994 | A |
| 5300052 | Kubo | Apr 1994 | A |
| 5304749 | Crandell | Apr 1994 | A |
| 5312383 | Kubalak | May 1994 | A |
| 5318550 | Cermak et al. | Jun 1994 | A |
| 5330459 | Lavon et al. | Jul 1994 | A |
| 5340840 | Park et al. | Aug 1994 | A |
| 5382244 | Telang | Jan 1995 | A |
| 5409014 | Napoli et al. | Apr 1995 | A |
| 5411495 | Willingham | May 1995 | A |
| 5423784 | Metz | Jun 1995 | A |
| 5456246 | Schmieding et al. | Oct 1995 | A |
| 5466229 | Elson et al. | Nov 1995 | A |
| 5478334 | Bernstein | Dec 1995 | A |
| 5499977 | Marx | Mar 1996 | A |
| 5543042 | Filan et al. | Aug 1996 | A |
| D373928 | Green | Sep 1996 | S |
| 5582604 | Ahr et al. | Dec 1996 | A |
| 5592950 | Kopelowicz | Jan 1997 | A |
| 5605161 | Cross | Feb 1997 | A |
| 5618277 | Goulter | Apr 1997 | A |
| 5628735 | Skow | May 1997 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5637104 | Ball et al. | Jun 1997 | A |
| 5674212 | Osborn et al. | Oct 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5678654 | Uzawa | Oct 1997 | A |
| 5687429 | Rahlff | Nov 1997 | A |
| 5695485 | Duperret et al. | Dec 1997 | A |
| 5700254 | Mcdowall et al. | Dec 1997 | A |
| 5701612 | Daneshvar | Dec 1997 | A |
| 5705777 | Flanigan et al. | Jan 1998 | A |
| 5752944 | Dann et al. | May 1998 | A |
| 5763333 | Suzuki et al. | Jun 1998 | A |
| 5772644 | Bark et al. | Jun 1998 | A |
| 5792132 | Garcia | Aug 1998 | A |
| 5827243 | Palestrant | Oct 1998 | A |
| 5827247 | Kay | Oct 1998 | A |
| 5827250 | Fujioka et al. | Oct 1998 | A |
| 5827257 | Fujioka et al. | Oct 1998 | A |
| D401699 | Herchenbach et al. | Nov 1998 | S |
| 5859393 | Cummins et al. | Jan 1999 | A |
| 5865378 | Hollinshead et al. | Feb 1999 | A |
| 5876393 | Ahr et al. | Mar 1999 | A |
| 5887291 | Bellizzi | Mar 1999 | A |
| 5891125 | Plumley | Apr 1999 | A |
| 5894608 | Birbara | Apr 1999 | A |
| D409303 | Oepping | May 1999 | S |
| 5911222 | Lawrence et al. | Jun 1999 | A |
| 5957904 | Holland | Sep 1999 | A |
| 5968026 | Osborn et al. | Oct 1999 | A |
| 5972505 | Phillips et al. | Oct 1999 | A |
| 6007526 | Passalaqua et al. | Dec 1999 | A |
| 6039060 | Rower | Mar 2000 | A |
| 6050983 | Moore et al. | Apr 2000 | A |
| 6059762 | Boyer et al. | May 2000 | A |
| 6063064 | Tuckey et al. | May 2000 | A |
| 6098625 | Winkler | Aug 2000 | A |
| 6105174 | Karlsten et al. | Aug 2000 | A |
| 6113582 | Dwork | Sep 2000 | A |
| 6117163 | Bierman | Sep 2000 | A |
| 6123398 | Arai et al. | Sep 2000 | A |
| 6129718 | Wada et al. | Oct 2000 | A |
| 6131964 | Sareshwala | Oct 2000 | A |
| 6152902 | Christian et al. | Nov 2000 | A |
| 6164569 | Hollinshead et al. | Dec 2000 | A |
| 6177606 | Etheredge et al. | Jan 2001 | B1 |
| 6209142 | Mattsson et al. | Apr 2001 | B1 |
| 6220050 | Cooksey | Apr 2001 | B1 |
| 6244311 | Hand et al. | Jun 2001 | B1 |
| 6248096 | Dwork et al. | Jun 2001 | B1 |
| 6263887 | Dunn | Jul 2001 | B1 |
| 6283246 | Nishikawa | Sep 2001 | B1 |
| 6311339 | Kraus | Nov 2001 | B1 |
| 6336919 | Davis et al. | Jan 2002 | B1 |
| 6338729 | Wada et al. | Jan 2002 | B1 |
| 6352525 | Wakabayashi | Mar 2002 | B1 |
| 6394988 | Hashimoto | May 2002 | B1 |
| 6398742 | Kim | Jun 2002 | B1 |
| 6406463 | Brown | Jun 2002 | B1 |
| 6409712 | Dutari et al. | Jun 2002 | B1 |
| 6416500 | Wada et al. | Jul 2002 | B1 |
| 6423045 | Wise et al. | Jul 2002 | B1 |
| 6428521 | Droll | Aug 2002 | B1 |
| 6428522 | Dipalma et al. | Aug 2002 | B1 |
| 6446454 | Lee et al. | Sep 2002 | B1 |
| 6475198 | Lipman et al. | Nov 2002 | B1 |
| 6479726 | Cole et al. | Nov 2002 | B1 |
| 6491673 | Palumbo et al. | Dec 2002 | B1 |
| 6508794 | Palumbo et al. | Jan 2003 | B1 |
| 6524292 | Dipalma et al. | Feb 2003 | B1 |
| 6540729 | Wada et al. | Apr 2003 | B1 |
| 6547771 | Robertson et al. | Apr 2003 | B2 |
| 6569133 | Cheng et al. | May 2003 | B2 |
| D476518 | Doppelt | Jul 2003 | S |
| 6592560 | Snyder et al. | Jul 2003 | B2 |
| 6610038 | Dipalma et al. | Aug 2003 | B1 |
| 6618868 | Minnick | Sep 2003 | B2 |
| 6620142 | Flueckiger | Sep 2003 | B1 |
| 6629651 | Male et al. | Oct 2003 | B1 |
| 6635038 | Scovel | Oct 2003 | B2 |
| 6652495 | Walker | Nov 2003 | B1 |
| 6666850 | Ahr et al. | Dec 2003 | B1 |
| 6685684 | Falconer | Feb 2004 | B1 |
| 6695828 | Dipalma et al. | Feb 2004 | B1 |
| 6699174 | Bennett | Mar 2004 | B1 |
| 6700034 | Lindsay et al. | Mar 2004 | B1 |
| 6702793 | Sweetser et al. | Mar 2004 | B1 |
| 6706027 | Harvie et al. | Mar 2004 | B2 |
| 6732384 | Scott | May 2004 | B2 |
| 6736977 | Hall et al. | May 2004 | B1 |
| 6740066 | Wolff et al. | May 2004 | B2 |
| 6764477 | Chen et al. | Jul 2004 | B1 |
| 6783519 | Samuelsson | Aug 2004 | B2 |
| 6796974 | Palumbo et al. | Sep 2004 | B2 |
| 6814547 | Childers et al. | Nov 2004 | B2 |
| 6849065 | Schmidt et al. | Feb 2005 | B2 |
| 6857137 | Otto | Feb 2005 | B2 |
| 6885690 | Aggerstam et al. | Apr 2005 | B2 |
| 6888044 | Fell et al. | May 2005 | B2 |
| 6893425 | Dunn et al. | May 2005 | B2 |
| 6912737 | Ernest et al. | Jul 2005 | B2 |
| 6918899 | Harvie | Jul 2005 | B2 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 7018366 | Easter | Mar 2006 | B2 |
| 7066411 | Male et al. | Jun 2006 | B2 |
| 7122023 | Hinoki | Oct 2006 | B1 |
| 7125399 | Miskie | Oct 2006 | B2 |
| 7131964 | Harvie | Nov 2006 | B2 |
| 7135012 | Harvie | Nov 2006 | B2 |
| 7141043 | Harvie | Nov 2006 | B2 |
| D533972 | La | Dec 2006 | S |
| 7160273 | Greter et al. | Jan 2007 | B2 |
| 7171699 | Ernest et al. | Feb 2007 | B2 |
| 7171871 | Kozak | Feb 2007 | B2 |
| 7179951 | Krishnaswamy-Mirle et al. | Feb 2007 | B2 |
| 7181781 | Trabold et al. | Feb 2007 | B1 |
| 7186245 | Cheng et al. | Mar 2007 | B1 |
| 7192424 | Cooper | Mar 2007 | B2 |
| 7219764 | Forbes | May 2007 | B1 |
| 7220250 | Suzuki et al. | May 2007 | B2 |
| D562975 | Otto | Feb 2008 | S |
| 7335189 | Harvie | Feb 2008 | B2 |
| 7358282 | Krueger et al. | Apr 2008 | B2 |
| 7390320 | Machida et al. | Jun 2008 | B2 |
| 7438706 | Koizumi et al. | Oct 2008 | B2 |
| 7488310 | Yang | Feb 2009 | B2 |
| 7491194 | Oliwa | Feb 2009 | B1 |
| D591106 | Dominique et al. | Apr 2009 | S |
| 7513381 | Heng et al. | Apr 2009 | B2 |
| 7520872 | Biggie et al. | Apr 2009 | B2 |
| D593801 | Wilson et al. | Jun 2009 | S |
| 7540364 | Sanderson | Jun 2009 | B2 |
| 7549511 | Marocco | Jun 2009 | B2 |
| 7549512 | Newberry | Jun 2009 | B2 |
| 7585293 | Vermaak | Sep 2009 | B2 |
| 7588560 | Dunlop | Sep 2009 | B1 |
| 7637905 | Saadat et al. | Dec 2009 | B2 |
| 7665359 | Barber | Feb 2010 | B2 |
| 7682347 | Parks et al. | Mar 2010 | B2 |
| 7687004 | Allen | Mar 2010 | B2 |
| 7695459 | Gilbert et al. | Apr 2010 | B2 |
| 7695460 | Wada et al. | Apr 2010 | B2 |
| 7699818 | Gilbert | Apr 2010 | B2 |
| 7699831 | Bengtson et al. | Apr 2010 | B2 |
| 7722584 | Tanaka et al. | May 2010 | B2 |
| 7727206 | Gorres | Jun 2010 | B2 |
| 7740620 | Gilbert et al. | Jun 2010 | B2 |
| 7749205 | Tazoe et al. | Jul 2010 | B2 |
| 7755497 | Wada et al. | Jul 2010 | B2 |
| 7766887 | Burns et al. | Aug 2010 | B2 |
| D625407 | Koizumi et al. | Oct 2010 | S |
| 7806879 | Brooks et al. | Oct 2010 | B2 |
| 7811272 | Lindsay et al. | Oct 2010 | B2 |
| 7815067 | Matsumoto et al. | Oct 2010 | B2 |
| 7833169 | Hannon | Nov 2010 | B2 |
| 7857806 | Karpowicz et al. | Dec 2010 | B2 |
| 7866942 | Harvie | Jan 2011 | B2 |
| 7871385 | Levinson et al. | Jan 2011 | B2 |
| 7875010 | Frazier et al. | Jan 2011 | B2 |
| 7901389 | Mombrinie | Mar 2011 | B2 |
| 7927320 | Goldwasser et al. | Apr 2011 | B2 |
| 7927321 | Marland | Apr 2011 | B2 |
| 7931634 | Swiecicki et al. | Apr 2011 | B2 |
| 7939706 | Okabe et al. | May 2011 | B2 |
| 7946443 | Stull et al. | May 2011 | B2 |
| 7947025 | Buglino et al. | May 2011 | B2 |
| 7963419 | Burney et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7993318 | Olsson et al. | Aug 2011 | B2 |
| 8015627 | Baker et al. | Sep 2011 | B2 |
| 8016071 | Martinus et al. | Sep 2011 | B1 |
| 8028460 | Williams | Oct 2011 | B2 |
| 8047398 | Dimartino et al. | Nov 2011 | B2 |
| 8083094 | Caulfield et al. | Dec 2011 | B2 |
| 8128608 | Thevenin | Mar 2012 | B2 |
| 8181651 | Pinel | May 2012 | B2 |
| 8181819 | Burney et al. | May 2012 | B2 |
| 8211063 | Bierman et al. | Jul 2012 | B2 |
| 8221369 | Parks et al. | Jul 2012 | B2 |
| 8241262 | Mahnensmith | Aug 2012 | B2 |
| 8277426 | Wilcox et al. | Oct 2012 | B2 |
| 8287508 | Sanchez | Oct 2012 | B1 |
| 8303554 | Tsai et al. | Nov 2012 | B2 |
| 8322565 | Caulfield et al. | Dec 2012 | B2 |
| 8337477 | Parks et al. | Dec 2012 | B2 |
| D674241 | Bickert et al. | Jan 2013 | S |
| 8343122 | Gorres | Jan 2013 | B2 |
| 8343125 | Kawazoe et al. | Jan 2013 | B2 |
| 8353074 | Krebs | Jan 2013 | B2 |
| 8353886 | Bester et al. | Jan 2013 | B2 |
| D676241 | Merrill | Feb 2013 | S |
| 8388588 | Wada et al. | Mar 2013 | B2 |
| D679807 | Burgess et al. | Apr 2013 | S |
| 8425482 | Khoubnazar | Apr 2013 | B2 |
| 8434586 | Pawelski et al. | May 2013 | B2 |
| 8449510 | Martini et al. | May 2013 | B2 |
| D684260 | Lund et al. | Jun 2013 | S |
| 8470230 | Caulfield et al. | Jun 2013 | B2 |
| 8479941 | Matsumoto et al. | Jul 2013 | B2 |
| 8479949 | Henkel | Jul 2013 | B2 |
| 8500719 | Simpson et al. | Aug 2013 | B1 |
| 8512301 | Ma | Aug 2013 | B2 |
| 8529530 | Koch et al. | Sep 2013 | B2 |
| 8535284 | Joder et al. | Sep 2013 | B2 |
| 8546639 | Wada et al. | Oct 2013 | B2 |
| 8551075 | Bengtson | Oct 2013 | B2 |
| 8568376 | Delattre et al. | Oct 2013 | B2 |
| D694404 | Burgess et al. | Nov 2013 | S |
| 8585683 | Bengtson et al. | Nov 2013 | B2 |
| 8652112 | Johannison et al. | Feb 2014 | B2 |
| 8669412 | Fernkvist et al. | Mar 2014 | B2 |
| D702973 | Norland et al. | Apr 2014 | S |
| 8703032 | Menon et al. | Apr 2014 | B2 |
| D704330 | Cicatelli | May 2014 | S |
| D704510 | Mason et al. | May 2014 | S |
| D705423 | Walsh Cutler | May 2014 | S |
| D705926 | Burgess et al. | May 2014 | S |
| 8714394 | Wulf | May 2014 | B2 |
| 8715267 | Bengtson et al. | May 2014 | B2 |
| 8757425 | Copeland | Jun 2014 | B2 |
| 8777032 | Biesecker et al. | Jul 2014 | B2 |
| 8808260 | Koch et al. | Aug 2014 | B2 |
| 8864730 | Conway et al. | Oct 2014 | B2 |
| 8881923 | Higginson | Nov 2014 | B2 |
| 8882731 | Suzuki et al. | Nov 2014 | B2 |
| 8936585 | Carson et al. | Jan 2015 | B2 |
| D729581 | Boroski | May 2015 | S |
| 9028460 | Medeiros | May 2015 | B2 |
| 9056698 | Noer | Jun 2015 | B2 |
| 9078792 | Ruiz | Jul 2015 | B2 |
| 9145879 | Pirovano et al. | Sep 2015 | B2 |
| 9173602 | Gilbert | Nov 2015 | B2 |
| 9173799 | Tanimoto et al. | Nov 2015 | B2 |
| 9187220 | Biesecker et al. | Nov 2015 | B2 |
| 9199772 | Krippendorf | Dec 2015 | B2 |
| 9233020 | Matsumiya | Jan 2016 | B2 |
| 9248058 | Conway et al. | Feb 2016 | B2 |
| 9308118 | Dupree et al. | Apr 2016 | B1 |
| 9309029 | Incorvia et al. | Apr 2016 | B2 |
| 9333281 | Giezendanner et al. | May 2016 | B2 |
| 9381108 | Longoni et al. | Jul 2016 | B2 |
| 9382047 | Schmidtner et al. | Jul 2016 | B2 |
| 9402424 | Roy | Aug 2016 | B2 |
| 9456937 | Ellis | Oct 2016 | B2 |
| 9480595 | Baham et al. | Nov 2016 | B2 |
| 9517865 | Albers et al. | Dec 2016 | B2 |
| D777941 | Piramoon | Jan 2017 | S |
| 9533806 | Ding et al. | Jan 2017 | B2 |
| 9550611 | Hodge | Jan 2017 | B2 |
| 9555930 | Campbell et al. | Jan 2017 | B2 |
| 9623159 | Locke | Apr 2017 | B2 |
| D789522 | Burgess et al. | Jun 2017 | S |
| 9687849 | Bruno et al. | Jun 2017 | B2 |
| 9694949 | Hendricks et al. | Jul 2017 | B2 |
| 9709048 | Kinjo | Jul 2017 | B2 |
| 9713547 | Lee et al. | Jul 2017 | B2 |
| 9732754 | Huang et al. | Aug 2017 | B2 |
| 9752564 | Arceno et al. | Sep 2017 | B2 |
| 9788992 | Harvie | Oct 2017 | B2 |
| D804907 | Sandoval | Dec 2017 | S |
| 9868564 | McGirr et al. | Jan 2018 | B2 |
| D814239 | Arora | Apr 2018 | S |
| D817484 | Lafond | May 2018 | S |
| 10037640 | Gordon | Jul 2018 | B2 |
| 10058470 | Phillips | Aug 2018 | B2 |
| 10098990 | Koch et al. | Oct 2018 | B2 |
| D835264 | Mozzicato et al. | Dec 2018 | S |
| D835779 | Mozzicato et al. | Dec 2018 | S |
| D840533 | Mozzicato et al. | Feb 2019 | S |
| D840534 | Mozzicato et al. | Feb 2019 | S |
| 10225376 | Perez Martinez | Mar 2019 | B2 |
| 10226376 | Sanchez et al. | Mar 2019 | B2 |
| 10258517 | Maschino et al. | Apr 2019 | B1 |
| D848612 | Mozzicato et al. | May 2019 | S |
| 10307305 | Hodges | Jun 2019 | B1 |
| 10335121 | Desai | Jul 2019 | B2 |
| D856512 | Cowart et al. | Aug 2019 | S |
| 10376406 | Newton | Aug 2019 | B2 |
| 10376407 | Newton | Aug 2019 | B2 |
| 10390989 | Sanchez et al. | Aug 2019 | B2 |
| D858144 | Fu | Sep 2019 | S |
| 10406039 | Mllarreal | Sep 2019 | B2 |
| 10407222 | Allen | Sep 2019 | B2 |
| 10478356 | Griffin | Nov 2019 | B2 |
| 10500108 | Maschino et al. | Dec 2019 | B1 |
| 10538366 | Pentelovitch et al. | Jan 2020 | B2 |
| 10569938 | Zhao et al. | Feb 2020 | B2 |
| 10577156 | Dagnelie et al. | Mar 2020 | B2 |
| RE47930 | Cho | Apr 2020 | E |
| 10618721 | Vazin | Apr 2020 | B2 |
| D884390 | Wang | May 2020 | S |
| 10669079 | Freedman et al. | Jun 2020 | B2 |
| D892315 | Airy | Aug 2020 | S |
| 10730672 | Bertram et al. | Aug 2020 | B2 |
| 10737848 | Philip et al. | Aug 2020 | B2 |
| 10765854 | Law et al. | Sep 2020 | B2 |
| 10766670 | Kittmann | Sep 2020 | B2 |
| 10799386 | Harrison | Oct 2020 | B1 |
| 10806642 | Tagomori et al. | Oct 2020 | B2 |
| D901214 | Hu | Nov 2020 | S |
| 10849799 | Nishikawa et al. | Dec 2020 | B2 |
| 10857025 | Davis et al. | Dec 2020 | B2 |
| 10865017 | Cowart et al. | Dec 2020 | B1 |
| 10889412 | West et al. | Jan 2021 | B2 |
| 10913581 | Stahlecker | Feb 2021 | B2 |
| D912244 | Rehm et al. | Mar 2021 | S |
| 10952889 | Newton et al. | Mar 2021 | B2 |
| 10973378 | Ryu et al. | Apr 2021 | B2 |
| 10973678 | Newton et al. | Apr 2021 | B2 |
| 10974874 | Ragias et al. | Apr 2021 | B2 |
| 11000401 | Ecklund et al. | May 2021 | B2 |
| D923365 | Wang | Jun 2021 | S |
| 11026829 | Harvie | Jun 2021 | B2 |
| 11027900 | Liu | Jun 2021 | B2 |
| 11045346 | Argent et al. | Jun 2021 | B2 |
| D928946 | Sanchez et al. | Aug 2021 | S |
| 11090183 | Sanchez et al. | Aug 2021 | B2 |
| 11160695 | Febo et al. | Nov 2021 | B2 |
| 11160697 | Maschino et al. | Nov 2021 | B2 |
| 11168420 | Kinugasa et al. | Nov 2021 | B2 |
| 11179506 | Barr et al. | Nov 2021 | B2 |
| 11226376 | Yamauchi et al. | Jan 2022 | B2 |
| 11253407 | Miao et al. | Feb 2022 | B2 |
| 11326586 | Milner et al. | May 2022 | B2 |
| 11369508 | Ecklund et al. | Jun 2022 | B2 |
| 11369524 | Hubbard et al. | Jun 2022 | B2 |
| 11376152 | Sanchez et al. | Jul 2022 | B2 |
| 11382786 | Sanchez et al. | Jul 2022 | B2 |
| 11382788 | Hjorth et al. | Jul 2022 | B2 |
| 11389318 | Radl et al. | Jul 2022 | B2 |
| 11395871 | Radl et al. | Jul 2022 | B2 |
| 11399990 | Suyama | Aug 2022 | B2 |
| 11426303 | Davis et al. | Aug 2022 | B2 |
| 11504265 | Godinez et al. | Nov 2022 | B2 |
| 11529252 | Glithero et al. | Dec 2022 | B2 |
| 11547788 | Radl et al. | Jan 2023 | B2 |
| 11806266 | Sanchez et al. | Nov 2023 | B2 |
| 11839567 | Davis et al. | Dec 2023 | B2 |
| D1010109 | Ecklund et al. | Jan 2024 | S |
| 11857716 | Lee et al. | Jan 2024 | B2 |
| 11865030 | Davis et al. | Jan 2024 | B2 |
| 11890221 | Ulreich et al. | Feb 2024 | B2 |
| 11925575 | Newton | Mar 2024 | B2 |
| 11938053 | Austermann et al. | Mar 2024 | B2 |
| 11944740 | Hughett et al. | Apr 2024 | B2 |
| 12023457 | Mann et al. | Jul 2024 | B2 |
| 12042422 | Davis et al. | Jul 2024 | B2 |
| 20010037097 | Cheng et al. | Nov 2001 | A1 |
| 20010054426 | Knudson et al. | Dec 2001 | A1 |
| 20020019614 | Woon | Feb 2002 | A1 |
| 20020026161 | Grundke | Feb 2002 | A1 |
| 20020087131 | Wolff et al. | Jul 2002 | A1 |
| 20020091364 | Prabhakar | Jul 2002 | A1 |
| 20020189992 | Schmidt et al. | Dec 2002 | A1 |
| 20020193760 | Thompson | Dec 2002 | A1 |
| 20030004436 | Schmidt et al. | Jan 2003 | A1 |
| 20030032931 | Grundke et al. | Feb 2003 | A1 |
| 20030032944 | Cawood | Feb 2003 | A1 |
| 20030073964 | Palumbo et al. | Apr 2003 | A1 |
| 20030120178 | Heki | Jun 2003 | A1 |
| 20030157859 | Ishikawa | Aug 2003 | A1 |
| 20030181880 | Schwartz | Sep 2003 | A1 |
| 20030195484 | Harvie | Oct 2003 | A1 |
| 20030204173 | Burns et al. | Oct 2003 | A1 |
| 20030233079 | Parks et al. | Dec 2003 | A1 |
| 20040006321 | Cheng et al. | Jan 2004 | A1 |
| 20040015141 | Cheng et al. | Jan 2004 | A1 |
| 20040056122 | Male et al. | Mar 2004 | A1 |
| 20040084465 | Luburic | May 2004 | A1 |
| 20040127872 | Petryk et al. | Jul 2004 | A1 |
| 20040128749 | Scott | Jul 2004 | A1 |
| 20040143229 | Easter | Jul 2004 | A1 |
| 20040147863 | Diaz et al. | Jul 2004 | A1 |
| 20040147894 | Mizutani et al. | Jul 2004 | A1 |
| 20040158221 | Mizutani et al. | Aug 2004 | A1 |
| 20040176731 | Cheng et al. | Sep 2004 | A1 |
| 20040176746 | Forral | Sep 2004 | A1 |
| 20040191919 | Unger et al. | Sep 2004 | A1 |
| 20040200936 | Opperthauser | Oct 2004 | A1 |
| 20040207530 | Nielsen | Oct 2004 | A1 |
| 20040236292 | Tazoe et al. | Nov 2004 | A1 |
| 20040243075 | Harvie | Dec 2004 | A1 |
| 20040254547 | Okabe et al. | Dec 2004 | A1 |
| 20050010182 | Parks et al. | Jan 2005 | A1 |
| 20050033248 | Machida et al. | Feb 2005 | A1 |
| 20050065471 | Kuntz | Mar 2005 | A1 |
| 20050070861 | Okabe et al. | Mar 2005 | A1 |
| 20050070862 | Tazoe et al. | Mar 2005 | A1 |
| 20050082300 | Modrell et al. | Apr 2005 | A1 |
| 20050097662 | Leimkuhler et al. | May 2005 | A1 |
| 20050101924 | Elson et al. | May 2005 | A1 |
| 20050119630 | Harvie | Jun 2005 | A1 |
| 20050137557 | Swiecicki et al. | Jun 2005 | A1 |
| 20050154360 | Harvie | Jul 2005 | A1 |
| 20050177070 | Levinson et al. | Aug 2005 | A1 |
| 20050197639 | Mombrinie | Sep 2005 | A1 |
| 20050273920 | Marinas | Dec 2005 | A1 |
| 20050277904 | Chase et al. | Dec 2005 | A1 |
| 20050279359 | Leblanc et al. | Dec 2005 | A1 |
| 20060004332 | Marx | Jan 2006 | A1 |
| 20060015080 | Mahnensmith | Jan 2006 | A1 |
| 20060015081 | Suzuki et al. | Jan 2006 | A1 |
| 20060016778 | Park | Jan 2006 | A1 |
| 20060069359 | Dipalma et al. | Mar 2006 | A1 |
| 20060079854 | Kay et al. | Apr 2006 | A1 |
| 20060111648 | Vermaak | May 2006 | A1 |
| 20060155214 | Wightman | Jul 2006 | A1 |
| 20060171997 | Gruenbacher et al. | Aug 2006 | A1 |
| 20060200102 | Cooper | Sep 2006 | A1 |
| 20060229575 | Boiarski | Oct 2006 | A1 |
| 20060229576 | Conway et al. | Oct 2006 | A1 |
| 20060231648 | Male et al. | Oct 2006 | A1 |
| 20060235266 | Nan | Oct 2006 | A1 |
| 20060235359 | Marland | Oct 2006 | A1 |
| 20060241553 | Harvie | Oct 2006 | A1 |
| 20060269439 | White | Nov 2006 | A1 |
| 20060277670 | Baker et al. | Dec 2006 | A1 |
| 20070006368 | Key et al. | Jan 2007 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070016152 | Karpowicz et al. | Jan 2007 | A1 |
| 20070038194 | Wada et al. | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070073252 | Forgrave | Mar 2007 | A1 |
| 20070117880 | Elson et al. | May 2007 | A1 |
| 20070118993 | Bates | May 2007 | A1 |
| 20070135786 | Schmidt et al. | Jun 2007 | A1 |
| 20070137718 | Rushlander et al. | Jun 2007 | A1 |
| 20070149935 | Dirico | Jun 2007 | A1 |
| 20070191804 | Coley | Aug 2007 | A1 |
| 20070203464 | Green et al. | Aug 2007 | A1 |
| 20070214553 | Carromba et al. | Sep 2007 | A1 |
| 20070225663 | Watt et al. | Sep 2007 | A1 |
| 20070225666 | Otto | Sep 2007 | A1 |
| 20070225668 | Otto | Sep 2007 | A1 |
| 20070266486 | Ramirez | Nov 2007 | A1 |
| 20070282309 | Bengtson et al. | Dec 2007 | A1 |
| 20080004576 | Tanaka et al. | Jan 2008 | A1 |
| 20080015526 | Reiner et al. | Jan 2008 | A1 |
| 20080015527 | House | Jan 2008 | A1 |
| 20080033386 | Okabe et al. | Feb 2008 | A1 |
| 20080041869 | Backaert | Feb 2008 | A1 |
| 20080091153 | Harvie | Apr 2008 | A1 |
| 20080091158 | Yang | Apr 2008 | A1 |
| 20080114327 | Barge | May 2008 | A1 |
| 20080167634 | Kouta et al. | Jul 2008 | A1 |
| 20080183157 | Walters | Jul 2008 | A1 |
| 20080215031 | Belfort et al. | Sep 2008 | A1 |
| 20080234642 | Patterson et al. | Sep 2008 | A1 |
| 20080269703 | Collins et al. | Oct 2008 | A1 |
| 20080281282 | Finger et al. | Nov 2008 | A1 |
| 20080287894 | Van Den Heuvel et al. | Nov 2008 | A1 |
| 20080312550 | Nishtala et al. | Dec 2008 | A1 |
| 20090025717 | Pinel | Jan 2009 | A1 |
| 20090048570 | Jensen | Feb 2009 | A1 |
| 20090056003 | Ivie et al. | Mar 2009 | A1 |
| 20090069761 | Vogel | Mar 2009 | A1 |
| 20090069765 | Wortham | Mar 2009 | A1 |
| 20090120179 | Nylander et al. | May 2009 | A1 |
| 20090192482 | Dodge et al. | Jul 2009 | A1 |
| 20090234312 | OToole et al. | Sep 2009 | A1 |
| 20090251510 | Noro et al. | Oct 2009 | A1 |
| 20090264840 | Mrginio | Oct 2009 | A1 |
| 20090270822 | Medeiros | Oct 2009 | A1 |
| 20090281510 | Fisher | Nov 2009 | A1 |
| 20100004612 | Thevenin | Jan 2010 | A1 |
| 20100058660 | Williams | Mar 2010 | A1 |
| 20100121289 | Parks et al. | May 2010 | A1 |
| 20100158168 | Murthy et al. | Jun 2010 | A1 |
| 20100160882 | Lowe | Jun 2010 | A1 |
| 20100174250 | Hu et al. | Jul 2010 | A1 |
| 20100185168 | Graauw et al. | Jul 2010 | A1 |
| 20100198172 | Wada et al. | Aug 2010 | A1 |
| 20100211032 | Tsai et al. | Aug 2010 | A1 |
| 20100234820 | Tsai et al. | Sep 2010 | A1 |
| 20100241104 | Gilbert | Sep 2010 | A1 |
| 20100263113 | Shelton et al. | Oct 2010 | A1 |
| 20100310845 | Bond et al. | Dec 2010 | A1 |
| 20110028920 | Johannison | Feb 2011 | A1 |
| 20110028922 | Kay et al. | Feb 2011 | A1 |
| 20110034889 | Smith | Feb 2011 | A1 |
| 20110036837 | Shang | Feb 2011 | A1 |
| 20110040267 | Wada et al. | Feb 2011 | A1 |
| 20110040271 | Rogers et al. | Feb 2011 | A1 |
| 20110054426 | Stewart et al. | Mar 2011 | A1 |
| 20110060299 | Wada et al. | Mar 2011 | A1 |
| 20110060300 | Weig et al. | Mar 2011 | A1 |
| 20110077495 | Gilbert | Mar 2011 | A1 |
| 20110077606 | Wilcox et al. | Mar 2011 | A1 |
| 20110087337 | Forsell | Apr 2011 | A1 |
| 20110137273 | Muellejans et al. | Jun 2011 | A1 |
| 20110145993 | Rader et al. | Jun 2011 | A1 |
| 20110152802 | Dicamillo et al. | Jun 2011 | A1 |
| 20110164147 | Takahashi et al. | Jul 2011 | A1 |
| 20110172620 | Khambatta | Jul 2011 | A1 |
| 20110172625 | Wada et al. | Jul 2011 | A1 |
| 20110202024 | Cozzens | Aug 2011 | A1 |
| 20110238023 | Slayton | Sep 2011 | A1 |
| 20110240648 | Tucker | Oct 2011 | A1 |
| 20110251572 | Nishtala et al. | Oct 2011 | A1 |
| 20110265889 | Tanaka et al. | Nov 2011 | A1 |
| 20110276020 | Mitsui | Nov 2011 | A1 |
| 20120029452 | Roedsten | Feb 2012 | A1 |
| 20120035577 | Tomes et al. | Feb 2012 | A1 |
| 20120041400 | Christensen | Feb 2012 | A1 |
| 20120059328 | Dikeman et al. | Mar 2012 | A1 |
| 20120066825 | Birbara et al. | Mar 2012 | A1 |
| 20120103347 | Wheaton et al. | May 2012 | A1 |
| 20120137420 | Gordon et al. | Jun 2012 | A1 |
| 20120165768 | Sekiyama et al. | Jun 2012 | A1 |
| 20120165786 | Chappa et al. | Jun 2012 | A1 |
| 20120210503 | Anzivino et al. | Aug 2012 | A1 |
| 20120233761 | Huang | Sep 2012 | A1 |
| 20120245541 | Suzuki et al. | Sep 2012 | A1 |
| 20120245542 | Suzuki et al. | Sep 2012 | A1 |
| 20120245547 | Wilcox et al. | Sep 2012 | A1 |
| 20120253303 | Suzuki et al. | Oct 2012 | A1 |
| 20120271259 | Ulert | Oct 2012 | A1 |
| 20120296305 | Barraza Khaled et al. | Nov 2012 | A1 |
| 20120316522 | Carter et al. | Dec 2012 | A1 |
| 20120330256 | Wilcox et al. | Dec 2012 | A1 |
| 20130006206 | Wada et al. | Jan 2013 | A1 |
| 20130045651 | Esteves et al. | Feb 2013 | A1 |
| 20130053804 | Soerensen et al. | Feb 2013 | A1 |
| 20130096523 | Chang et al. | Apr 2013 | A1 |
| 20130110059 | Kossow et al. | May 2013 | A1 |
| 20130138064 | Stroebech et al. | May 2013 | A1 |
| 20130150813 | Gordon et al. | Jun 2013 | A1 |
| 20130218112 | Thompson | Aug 2013 | A1 |
| 20130245496 | Wells et al. | Sep 2013 | A1 |
| 20130245586 | Jha | Sep 2013 | A1 |
| 20130292537 | Dirico | Nov 2013 | A1 |
| 20130330501 | Aizenberg et al. | Dec 2013 | A1 |
| 20140005647 | Shuffler et al. | Jan 2014 | A1 |
| 20140031774 | Bengtson | Jan 2014 | A1 |
| 20140039432 | Dunbar et al. | Feb 2014 | A1 |
| 20140157499 | Suzuki et al. | Jun 2014 | A1 |
| 20140171889 | Hopman et al. | Jun 2014 | A1 |
| 20140182051 | Tanimoto et al. | Jul 2014 | A1 |
| 20140196189 | Lee et al. | Jul 2014 | A1 |
| 20140276501 | Cisko | Sep 2014 | A1 |
| 20140303582 | Wright et al. | Oct 2014 | A1 |
| 20140316381 | Reglin | Oct 2014 | A1 |
| 20140325746 | Block | Nov 2014 | A1 |
| 20140348139 | Gomez Martinez | Nov 2014 | A1 |
| 20140352050 | Yao et al. | Dec 2014 | A1 |
| 20140371628 | Desai | Dec 2014 | A1 |
| 20150045757 | Lee | Feb 2015 | A1 |
| 20150047114 | Ramirez | Feb 2015 | A1 |
| 20150048089 | Robertson | Feb 2015 | A1 |
| 20150135423 | Sharpe et al. | May 2015 | A1 |
| 20150157300 | Ealovega et al. | Jun 2015 | A1 |
| 20150209194 | Heyman | Jul 2015 | A1 |
| 20150290425 | Macy et al. | Oct 2015 | A1 |
| 20150320583 | Harvie | Nov 2015 | A1 |
| 20150329255 | Rzepecki | Nov 2015 | A1 |
| 20150342799 | Michiels et al. | Dec 2015 | A1 |
| 20150359660 | Harvie | Dec 2015 | A1 |
| 20150366699 | Nelson | Dec 2015 | A1 |
| 20160029998 | Brister et al. | Feb 2016 | A1 |
| 20160030228 | Jones | Feb 2016 | A1 |
| 20160038356 | Yao et al. | Feb 2016 | A1 |
| 20160058322 | Brister et al. | Mar 2016 | A1 |
| 20160060001 | Wada et al. | Mar 2016 | A1 |
| 20160100976 | Conway et al. | Apr 2016 | A1 |
| 20160106604 | Timm | Apr 2016 | A1 |
| 20160113809 | Kim | Apr 2016 | A1 |
| 20160183689 | Miner | Jun 2016 | A1 |
| 20160256022 | Le | Sep 2016 | A1 |
| 20160270982 | Raycheck et al. | Sep 2016 | A1 |
| 20160278662 | Brister et al. | Sep 2016 | A1 |
| 20160357400 | Penha et al. | Dec 2016 | A1 |
| 20160366699 | Zhang et al. | Dec 2016 | A1 |
| 20160367226 | Newton et al. | Dec 2016 | A1 |
| 20160367411 | Justiz et al. | Dec 2016 | A1 |
| 20160367726 | Gratzer | Dec 2016 | A1 |
| 20160374848 | Sanchez et al. | Dec 2016 | A1 |
| 20170007438 | Harvie | Jan 2017 | A1 |
| 20170014560 | Minskoff et al. | Jan 2017 | A1 |
| 20170100276 | Joh | Apr 2017 | A1 |
| 20170128638 | Giezendanner et al. | May 2017 | A1 |
| 20170136209 | Burnett et al. | May 2017 | A1 |
| 20170143534 | Sanchez | May 2017 | A1 |
| 20170165100 | Jackson et al. | Jun 2017 | A1 |
| 20170165405 | Muser et al. | Jun 2017 | A1 |
| 20170189225 | Voorhees et al. | Jul 2017 | A1 |
| 20170202692 | Laniado | Jul 2017 | A1 |
| 20170216081 | Accosta | Aug 2017 | A1 |
| 20170246026 | Laniado | Aug 2017 | A1 |
| 20170252014 | Siller Gonzalez et al. | Sep 2017 | A1 |
| 20170252202 | Sanchez et al. | Sep 2017 | A9 |
| 20170266031 | Sanchez et al. | Sep 2017 | A1 |
| 20170266658 | Bruno et al. | Sep 2017 | A1 |
| 20170281399 | Vanmiddendorp et al. | Oct 2017 | A1 |
| 20170312116 | Laniado | Nov 2017 | A1 |
| 20170325788 | Ealovega et al. | Nov 2017 | A1 |
| 20170333244 | Laniado | Nov 2017 | A1 |
| 20170042748 | Griffin | Dec 2017 | A1 |
| 20170348139 | Newton et al. | Dec 2017 | A1 |
| 20170354532 | Holt | Dec 2017 | A1 |
| 20170354551 | Gawley et al. | Dec 2017 | A1 |
| 20170367873 | Grannum | Dec 2017 | A1 |
| 20180002075 | Lee | Jan 2018 | A1 |
| 20180008451 | Stroebech | Jan 2018 | A1 |
| 20180008804 | Laniado | Jan 2018 | A1 |
| 20180021218 | Brosch et al. | Jan 2018 | A1 |
| 20180028349 | Newton et al. | Feb 2018 | A1 |
| 20180037384 | Archeny et al. | Feb 2018 | A1 |
| 20180049910 | Newton | Feb 2018 | A1 |
| 20180064572 | Wiltshire | Mar 2018 | A1 |
| 20180104131 | Killian | Apr 2018 | A1 |
| 20180127187 | Sewell | May 2018 | A1 |
| 20180193215 | Davies et al. | Jul 2018 | A1 |
| 20180200101 | Su | Jul 2018 | A1 |
| 20180228642 | Davis et al. | Aug 2018 | A1 |
| 20180256384 | Kasirye | Sep 2018 | A1 |
| 20180271694 | Fernandez et al. | Sep 2018 | A1 |
| 20180317892 | Catlin | Nov 2018 | A1 |
| 20180325748 | Sharma et al. | Nov 2018 | A1 |
| 20190001030 | Braga et al. | Jan 2019 | A1 |
| 20190021899 | Vlet | Jan 2019 | A1 |
| 20190038451 | Harvie | Feb 2019 | A1 |
| 20190046102 | Kushnir et al. | Feb 2019 | A1 |
| 20190059938 | Holsten | Feb 2019 | A1 |
| 20190091059 | Gabriel | Mar 2019 | A1 |
| 20190100362 | Meyers et al. | Apr 2019 | A1 |
| 20190133814 | Tammen et al. | May 2019 | A1 |
| 20190142624 | Sanchez et al. | May 2019 | A1 |
| 20190224036 | Sanchez et al. | Jul 2019 | A1 |
| 20190247222 | Ecklund et al. | Aug 2019 | A1 |
| 20190247223 | Brun et al. | Aug 2019 | A1 |
| 20190282391 | Johannes et al. | Sep 2019 | A1 |
| 20190314189 | Acosta | Oct 2019 | A1 |
| 20190314190 | Sanchez et al. | Oct 2019 | A1 |
| 20190321587 | Mcmenamin et al. | Oct 2019 | A1 |
| 20190344934 | Faerber et al. | Nov 2019 | A1 |
| 20190365307 | Laing et al. | Dec 2019 | A1 |
| 20190365561 | Newton et al. | Dec 2019 | A1 |
| 20200008985 | Nguyen et al. | Jan 2020 | A1 |
| 20200016012 | Dutkiewicz | Jan 2020 | A1 |
| 20200030595 | Boukidjian et al. | Jan 2020 | A1 |
| 20200046544 | Godinez et al. | Feb 2020 | A1 |
| 20200055638 | Lau et al. | Feb 2020 | A1 |
| 20200070392 | Huber et al. | Mar 2020 | A1 |
| 20200085609 | Schelch et al. | Mar 2020 | A1 |
| 20200085610 | Cohn et al. | Mar 2020 | A1 |
| 20200086090 | Von Weymarn-schärli et al. | Mar 2020 | A1 |
| 20200107518 | Hiroshima et al. | Apr 2020 | A1 |
| 20200129322 | Leuckel | Apr 2020 | A1 |
| 20200171217 | Braga et al. | Jun 2020 | A9 |
| 20200206039 | Mclain | Jul 2020 | A1 |
| 20200214910 | Varona et al. | Jul 2020 | A1 |
| 20200216898 | Hubbell | Jul 2020 | A1 |
| 20200216989 | Kinugasa et al. | Jul 2020 | A1 |
| 20200229964 | Staali et al. | Jul 2020 | A1 |
| 20200231343 | Freedman et al. | Jul 2020 | A1 |
| 20200232841 | Satish et al. | Jul 2020 | A1 |
| 20200246172 | Ho | Aug 2020 | A1 |
| 20200246203 | Tulk et al. | Aug 2020 | A1 |
| 20200255189 | Liu | Aug 2020 | A1 |
| 20200261280 | Heyman | Aug 2020 | A1 |
| 20200276046 | Staali et al. | Sep 2020 | A1 |
| 20200306075 | Newton et al. | Oct 2020 | A1 |
| 20200315837 | Radl et al. | Oct 2020 | A1 |
| 20200315838 | Eckert | Oct 2020 | A1 |
| 20200315872 | Viens et al. | Oct 2020 | A1 |
| 20200315874 | Viens et al. | Oct 2020 | A1 |
| 20200331672 | Bertram et al. | Oct 2020 | A1 |
| 20200345332 | Duval | Nov 2020 | A1 |
| 20200353135 | Gregory et al. | Nov 2020 | A1 |
| 20200367677 | Silsby et al. | Nov 2020 | A1 |
| 20200369444 | Silsby et al. | Nov 2020 | A1 |
| 20200375781 | Staali et al. | Dec 2020 | A1 |
| 20200375810 | Carlin et al. | Dec 2020 | A1 |
| 20200385179 | McCourt | Dec 2020 | A1 |
| 20200390591 | Glithero et al. | Dec 2020 | A1 |
| 20200390592 | Merrill | Dec 2020 | A1 |
| 20200405521 | Glasroe | Dec 2020 | A1 |
| 20210008771 | Huber et al. | Jan 2021 | A1 |
| 20210009323 | Markarian et al. | Jan 2021 | A1 |
| 20210020072 | Moehring et al. | Jan 2021 | A1 |
| 20210059853 | Davis et al. | Mar 2021 | A1 |
| 20210061523 | Bytheway | Mar 2021 | A1 |
| 20210069005 | Sanchez et al. | Mar 2021 | A1 |
| 20210069008 | Blabas et al. | Mar 2021 | A1 |
| 20210069009 | Im | Mar 2021 | A1 |
| 20210069030 | Nishikawa et al. | Mar 2021 | A1 |
| 20210077993 | Nazareth et al. | Mar 2021 | A1 |
| 20210113749 | Radl et al. | Apr 2021 | A1 |
| 20210121318 | Pinlac | Apr 2021 | A1 |
| 20210137724 | Ecklund et al. | May 2021 | A1 |
| 20210138190 | Erbey et al. | May 2021 | A1 |
| 20210154055 | Mllarreal | May 2021 | A1 |
| 20210170079 | Radl et al. | Jun 2021 | A1 |
| 20210178390 | Oueslati et al. | Jun 2021 | A1 |
| 20210186742 | Newton et al. | Jun 2021 | A1 |
| 20210212865 | Wallajapet et al. | Jul 2021 | A1 |
| 20210220162 | Jamison | Jul 2021 | A1 |
| 20210220163 | Mayrand | Jul 2021 | A1 |
| 20210228400 | Glithero | Jul 2021 | A1 |
| 20210228401 | Becker et al. | Jul 2021 | A1 |
| 20210228795 | Hughett et al. | Jul 2021 | A1 |
| 20210229877 | Ragias et al. | Jul 2021 | A1 |
| 20210236323 | Austermann et al. | Aug 2021 | A1 |
| 20210236324 | Sweeney | Aug 2021 | A1 |
| 20210251814 | Jönegren et al. | Aug 2021 | A1 |
| 20210267787 | Nazemi | Sep 2021 | A1 |
| 20210275343 | Sanchez et al. | Sep 2021 | A1 |
| 20210275344 | Wing | Sep 2021 | A1 |
| 20210290454 | Yamada | Sep 2021 | A1 |
| 20210315727 | Jiang | Oct 2021 | A1 |
| 20210353450 | Sharma et al. | Nov 2021 | A1 |
| 20210361469 | Liu et al. | Nov 2021 | A1 |
| 20210369495 | Cheng et al. | Dec 2021 | A1 |
| 20210386925 | Hartwell et al. | Dec 2021 | A1 |
| 20210393433 | Godinez et al. | Dec 2021 | A1 |
| 20220023091 | Ecklund et al. | Jan 2022 | A1 |
| 20220031523 | Pierpoint | Feb 2022 | A1 |
| 20220039995 | Johannes et al. | Feb 2022 | A1 |
| 20220047410 | Walthall | Feb 2022 | A1 |
| 20220062027 | Mitchell et al. | Mar 2022 | A1 |
| 20220062028 | Mitchell et al. | Mar 2022 | A1 |
| 20220062029 | Johannes et al. | Mar 2022 | A1 |
| 20220066825 | Saraf et al. | Mar 2022 | A1 |
| 20220071811 | Cheng et al. | Mar 2022 | A1 |
| 20220071826 | Kulkarni et al. | Mar 2022 | A1 |
| 20220104965 | Vaninetti et al. | Apr 2022 | A1 |
| 20220104976 | Hoeger et al. | Apr 2022 | A1 |
| 20220104981 | Jones | Apr 2022 | A1 |
| 20220117773 | Davis et al. | Apr 2022 | A1 |
| 20220117774 | Meyer et al. | Apr 2022 | A1 |
| 20220117775 | Jones et al. | Apr 2022 | A1 |
| 20220133524 | Davis | May 2022 | A1 |
| 20220151817 | Mann | May 2022 | A1 |
| 20220160949 | Simiele et al. | May 2022 | A1 |
| 20220168159 | Triado et al. | Jun 2022 | A1 |
| 20220193312 | Lee et al. | Jun 2022 | A1 |
| 20220211536 | Johannes et al. | Jul 2022 | A1 |
| 20220218510 | Metzger et al. | Jul 2022 | A1 |
| 20220229053 | Levin et al. | Jul 2022 | A1 |
| 20220241106 | Johannes et al. | Aug 2022 | A1 |
| 20220247407 | Yamamoto et al. | Aug 2022 | A1 |
| 20220248836 | Cagle et al. | Aug 2022 | A1 |
| 20220257407 | Johannes et al. | Aug 2022 | A1 |
| 20220265460 | Coker | Aug 2022 | A1 |
| 20220265462 | Alder et al. | Aug 2022 | A1 |
| 20220270711 | Feala et al. | Aug 2022 | A1 |
| 20220273482 | Johannes et al. | Sep 2022 | A1 |
| 20220280357 | Jagannathan et al. | Sep 2022 | A1 |
| 20220287689 | Johannes | Sep 2022 | A1 |
| 20220296408 | Evans et al. | Sep 2022 | A1 |
| 20220305191 | Joseph et al. | Sep 2022 | A1 |
| 20220313222 | Austermann et al. | Oct 2022 | A1 |
| 20220313474 | Kriscovich et al. | Oct 2022 | A1 |
| 20220331170 | Erdem et al. | Oct 2022 | A1 |
| 20220339024 | Johannes et al. | Oct 2022 | A1 |
| 20220354685 | Davis et al. | Nov 2022 | A1 |
| 20220362049 | Austermann et al. | Nov 2022 | A1 |
| 20220370231 | Wang et al. | Nov 2022 | A1 |
| 20220370234 | Hughett et al. | Nov 2022 | A1 |
| 20220370235 | Johannes et al. | Nov 2022 | A1 |
| 20220370237 | Parmar et al. | Nov 2022 | A1 |
| 20220387001 | Askenazi et al. | Dec 2022 | A1 |
| 20220395390 | Brooks | Dec 2022 | A1 |
| 20220395391 | Saunders et al. | Dec 2022 | A1 |
| 20230018845 | Lee | Jan 2023 | A1 |
| 20230020563 | Sharma et al. | Jan 2023 | A1 |
| 20230031640 | Hughett et al. | Feb 2023 | A1 |
| 20230037159 | Brennan et al. | Feb 2023 | A1 |
| 20230052238 | Oluwasogo | Feb 2023 | A1 |
| 20230062994 | Ecklund et al. | Mar 2023 | A1 |
| 20230070347 | Watson et al. | Mar 2023 | A1 |
| 20230073708 | Xu et al. | Mar 2023 | A1 |
| 20230089032 | Hughett et al. | Mar 2023 | A1 |
| 20230099821 | Radl et al. | Mar 2023 | A1 |
| 20230099991 | Bianchi et al. | Mar 2023 | A1 |
| 20230105001 | Whittome et al. | Apr 2023 | A1 |
| 20230110577 | Choi | Apr 2023 | A1 |
| 20230138269 | Abdelal et al. | May 2023 | A1 |
| 20230145365 | Martin et al. | May 2023 | A1 |
| 20230155253 | Mn et al. | May 2023 | A1 |
| 20230210504 | Kuroda et al. | Jul 2023 | A1 |
| 20230210685 | Fallows et al. | Jul 2023 | A1 |
| 20230218426 | Hughett | Jul 2023 | A1 |
| 20230240884 | Davis et al. | Aug 2023 | A1 |
| 20230248562 | Sanchez et al. | Aug 2023 | A1 |
| 20230248564 | Mann et al. | Aug 2023 | A1 |
| 20230255812 | Sanchez et al. | Aug 2023 | A1 |
| 20230255813 | Sanchez et al. | Aug 2023 | A1 |
| 20230255815 | Newton | Aug 2023 | A1 |
| 20230263650 | Sanchez et al. | Aug 2023 | A1 |
| 20230263655 | Johannes et al. | Aug 2023 | A1 |
| 20230277362 | Davis et al. | Sep 2023 | A1 |
| 20230285178 | Sanchez et al. | Sep 2023 | A1 |
| 20230293339 | James | Sep 2023 | A1 |
| 20230301846 | Greenwood | Sep 2023 | A1 |
| 20230355423 | Stevenson et al. | Nov 2023 | A1 |
| 20230404791 | Ecklund et al. | Dec 2023 | A1 |
| 20240008444 | Su et al. | Jan 2024 | A1 |
| 20240009023 | Johannes et al. | Jan 2024 | A1 |
| 20240024170 | Scott | Jan 2024 | A1 |
| 20240041638 | Johannes et al. | Feb 2024 | A1 |
| 20240058161 | Ulreich et al. | Feb 2024 | A1 |
| 20240065881 | Kuroda et al. | Feb 2024 | A1 |
| 20240099874 | Sanchez et al. | Mar 2024 | A1 |
| 20240110318 | Bendt et al. | Apr 2024 | A1 |
| 20240123134 | Kharkar et al. | Apr 2024 | A1 |
| Number | Date | Country |
|---|---|---|
| 2018216821 | Aug 2019 | AU |
| 2021299304 | Feb 2023 | AU |
| 2165286 | Sep 1999 | CA |
| 2354132 | Jun 2000 | CA |
| 2359091 | Sep 2003 | CA |
| 2488867 | Aug 2007 | CA |
| 3050918 | Aug 2018 | CA |
| 3098571 | Nov 2019 | CA |
| 2269203 | Dec 1997 | CN |
| 1332620 | Jan 2002 | CN |
| 1434693 | Aug 2003 | CN |
| 1533755 | Oct 2004 | CN |
| 1602825 | Apr 2005 | CN |
| 1720888 | Jan 2006 | CN |
| 2936204 | Aug 2007 | CN |
| 101262836 | Sep 2008 | CN |
| 101522148 | Sep 2009 | CN |
| 102159159 | Aug 2011 | CN |
| 202184840 | Apr 2012 | CN |
| 102481441 | May 2012 | CN |
| 202463712 | Oct 2012 | CN |
| 103533968 | Jan 2014 | CN |
| 103717180 | Apr 2014 | CN |
| 204562697 | Aug 2015 | CN |
| 105411783 | Mar 2016 | CN |
| 105451693 | Mar 2016 | CN |
| 105534632 | May 2016 | CN |
| 205849719 | Jan 2017 | CN |
| 106726089 | May 2017 | CN |
| 107847384 | Mar 2018 | CN |
| 107920912 | Apr 2018 | CN |
| 108420590 | Aug 2018 | CN |
| 209285902 | Aug 2019 | CN |
| 110381883 | Oct 2019 | CN |
| 211198839 | Aug 2020 | CN |
| 112566550 | Mar 2021 | CN |
| 112603184 | Apr 2021 | CN |
| 114007493 | Feb 2022 | CN |
| 114375187 | Apr 2022 | CN |
| 116096332 | May 2023 | CN |
| 79818 | Oct 1893 | DE |
| 1516466 | Jun 1969 | DE |
| 2721330 | Nov 1977 | DE |
| 2742298 | Mar 1978 | DE |
| 9407554.9 | May 1995 | DE |
| 4443710 | Jun 1995 | DE |
| 4416094 | Nov 1995 | DE |
| 4236097 | Oct 1996 | DE |
| 19619597 | Nov 1997 | DE |
| 102005037762 | Sep 2006 | DE |
| 102011103783 | Dec 2012 | DE |
| 202015104597 | Jul 2016 | DE |
| 102020121462 | Jan 2022 | DE |
| 9600118 | Nov 1996 | DK |
| 0032138 | Jul 1981 | EP |
| 0066070 | Dec 1982 | EP |
| 0068712 | Jan 1983 | EP |
| 0140470 | May 1985 | EP |
| 0140471 | May 1988 | EP |
| 0274753 | Jul 1988 | EP |
| 0119143 | Nov 1988 | EP |
| 0483592 | May 1992 | EP |
| 0610638 | Aug 1994 | EP |
| 0613355 | Sep 1994 | EP |
| 0613355 | Jan 1997 | EP |
| 0787472 | Aug 1997 | EP |
| 0966936 | Dec 1999 | EP |
| 0987293 | Mar 2000 | EP |
| 1063953 | Jan 2001 | EP |
| 0653928 | Oct 2002 | EP |
| 1332738 | Aug 2003 | EP |
| 1382318 | Jan 2004 | EP |
| 1089684 | Oct 2004 | EP |
| 1616542 | Jan 2006 | EP |
| 1382318 | May 2006 | EP |
| 1063953 | Jan 2007 | EP |
| 1872752 | Jan 2008 | EP |
| 2180907 | May 2010 | EP |
| 2380532 | Oct 2011 | EP |
| 2389908 | Nov 2011 | EP |
| 2601916 | Jun 2013 | EP |
| 2676643 | Dec 2013 | EP |
| 2997950 | Mar 2016 | EP |
| 2879534 | Mar 2017 | EP |
| 3424471 | Jan 2019 | EP |
| 3169292 | Nov 2019 | EP |
| 3753492 | Dec 2020 | EP |
| 3788992 | Mar 2021 | EP |
| 3576689 | Mar 2022 | EP |
| 3752110 | Mar 2022 | EP |
| 3787570 | Mar 2022 | EP |
| 4025163 | Jul 2022 | EP |
| 3463180 | Mar 2023 | EP |
| 3569205 | Jun 2023 | EP |
| 4382082 | Jun 2024 | EP |
| 871820 | Jul 1961 | GB |
| 1011517 | Dec 1965 | GB |
| 1467144 | Mar 1977 | GB |
| 2106395 | Apr 1983 | GB |
| 2106784 | Apr 1983 | GB |
| 2148126 | May 1985 | GB |
| 2171315 | Aug 1986 | GB |
| 2181953 | May 1987 | GB |
| 2148126 | Jul 1987 | GB |
| 2191095 | Dec 1987 | GB |
| 2199750 | Jul 1988 | GB |
| 2260907 | May 1993 | GB |
| 2462267 | Feb 2010 | GB |
| 2469496 | Oct 2010 | GB |
| 2490327 | Oct 2012 | GB |
| 2507318 | Apr 2014 | GB |
| 2612752 | May 2023 | GB |
| 201800009129 | Apr 2020 | IT |
| S498638 | Jan 1974 | JP |
| S5410596 | Jan 1979 | JP |
| S5410596 | May 1979 | JP |
| S55155618 | Dec 1980 | JP |
| S5888596 | Jun 1983 | JP |
| S63107780 | Jul 1988 | JP |
| H0267530 | Mar 1990 | JP |
| H02103871 | Apr 1990 | JP |
| H02131422 | May 1990 | JP |
| H02131422 | Nov 1990 | JP |
| H0460220 | Feb 1992 | JP |
| H05123349 | May 1993 | JP |
| H05123350 | May 1993 | JP |
| 3087938 | Oct 1995 | JP |
| H085630 | Jan 1996 | JP |
| H1040141 | Feb 1998 | JP |
| H10225430 | Aug 1998 | JP |
| H11113946 | Apr 1999 | JP |
| H11290365 | Oct 1999 | JP |
| 2000116690 | Apr 2000 | JP |
| 2000185068 | Jul 2000 | JP |
| 2001054531 | Feb 2001 | JP |
| 2001070331 | Mar 2001 | JP |
| 2001224616 | Aug 2001 | JP |
| 2001276107 | Oct 2001 | JP |
| 2001276108 | Oct 2001 | JP |
| 2002028173 | Jan 2002 | JP |
| 2003505152 | Feb 2003 | JP |
| 2003126242 | May 2003 | JP |
| 2003180722 | Jul 2003 | JP |
| 2003528691 | Sep 2003 | JP |
| 2004057578 | Feb 2004 | JP |
| 2004130056 | Apr 2004 | JP |
| 2004267530 | Sep 2004 | JP |
| 2005052219 | Mar 2005 | JP |
| 2005066011 | Mar 2005 | JP |
| 2005066325 | Mar 2005 | JP |
| 2005102978 | Apr 2005 | JP |
| 2005518237 | Jun 2005 | JP |
| 3749097 | Dec 2005 | JP |
| 2006026108 | Feb 2006 | JP |
| 3123547 | Jun 2006 | JP |
| 2006136492 | Jun 2006 | JP |
| 2006204868 | Aug 2006 | JP |
| 2007044494 | Feb 2007 | JP |
| 3132659 | May 2007 | JP |
| 2007209687 | Aug 2007 | JP |
| 4039641 | Nov 2007 | JP |
| 2008005975 | Jan 2008 | JP |
| 2009509570 | Mar 2009 | JP |
| 2009165887 | Jul 2009 | JP |
| 2010504150 | Feb 2010 | JP |
| 2010081981 | Apr 2010 | JP |
| 4640772 | Dec 2010 | JP |
| 2010536439 | Dec 2010 | JP |
| 2011500225 | Jan 2011 | JP |
| 2011030962 | Feb 2011 | JP |
| 4747166 | May 2011 | JP |
| 2011087823 | May 2011 | JP |
| 4801218 | Aug 2011 | JP |
| 2011218130 | Nov 2011 | JP |
| 2011224070 | Nov 2011 | JP |
| 3175719 | Apr 2012 | JP |
| 2012523869 | Oct 2012 | JP |
| 2013238608 | Nov 2013 | JP |
| 2014521960 | Aug 2014 | JP |
| 2015092945 | May 2015 | JP |
| 3198994 | Jul 2015 | JP |
| 2016521191 | Jul 2016 | JP |
| 2017014698 | Jan 2017 | JP |
| 2019525811 | Sep 2019 | JP |
| 2019170942 | Oct 2019 | JP |
| 2019533492 | Nov 2019 | JP |
| 2021120686 | Aug 2021 | JP |
| 2021522009 | Aug 2021 | JP |
| 2021522013 | Aug 2021 | JP |
| 7129493 | Aug 2022 | JP |
| 2023532132 | Jul 2023 | JP |
| 200290061 | Sep 2002 | KR |
| 20030047451 | Jun 2003 | KR |
| 20140039485 | Apr 2014 | KR |
| 101432639 | Aug 2014 | KR |
| 20180106659 | Oct 2018 | KR |
| 20180108774 | Oct 2018 | KR |
| 2068717 | Jun 2013 | PT |
| 505542 | Sep 1997 | SE |
| 8101957 | Jul 1981 | WO |
| 8804558 | Jun 1988 | WO |
| 9104714 | Apr 1991 | WO |
| 9104714 | Jun 1991 | WO |
| 9220299 | Feb 1993 | WO |
| 9307839 | Apr 1993 | WO |
| 9309736 | May 1993 | WO |
| 9309736 | Jun 1993 | WO |
| 9514448 | Jun 1995 | WO |
| 9600096 | Jan 1996 | WO |
| 9634636 | Nov 1996 | WO |
| 9817211 | Apr 1998 | WO |
| 9830336 | Jul 1998 | WO |
| 0000112 | Jan 2000 | WO |
| 0000113 | Jan 2000 | WO |
| 0025651 | May 2000 | WO |
| 0033773 | Jun 2000 | WO |
| 0057784 | Oct 2000 | WO |
| 0069377 | Nov 2000 | WO |
| 0079497 | Dec 2000 | WO |
| 0145618 | Jun 2001 | WO |
| 0145621 | Jun 2001 | WO |
| 02094160 | Nov 2002 | WO |
| 03013967 | Feb 2003 | WO |
| 03024824 | Mar 2003 | WO |
| 03055423 | Jul 2003 | WO |
| 03071931 | Sep 2003 | WO |
| 03079942 | Oct 2003 | WO |
| 03071931 | Feb 2004 | WO |
| 2004019836 | Mar 2004 | WO |
| 2004024046 | Mar 2004 | WO |
| 2004026195 | Apr 2004 | WO |
| 2005051252 | Jun 2005 | WO |
| 2005074571 | Sep 2005 | WO |
| 2005089687 | Sep 2005 | WO |
| 2005107661 | Nov 2005 | WO |
| 2006021220 | Mar 2006 | WO |
| 2006037140 | Apr 2006 | WO |
| 2007005851 | Jan 2007 | WO |
| 2007007845 | Jan 2007 | WO |
| 2007042823 | Apr 2007 | WO |
| 2007055651 | May 2007 | WO |
| 2006098950 | Nov 2007 | WO |
| 2007134608 | Nov 2007 | WO |
| 2007128156 | Feb 2008 | WO |
| 2008026106 | Mar 2008 | WO |
| 2008078117 | Jul 2008 | WO |
| 2008104019 | Sep 2008 | WO |
| 2008141471 | Nov 2008 | WO |
| 2009004368 | Jan 2009 | WO |
| 2009004369 | Jan 2009 | WO |
| 2009052496 | Apr 2009 | WO |
| 2009052502 | Apr 2009 | WO |
| 2009007702 | Jul 2009 | WO |
| 2009101738 | Aug 2009 | WO |
| 2010058192 | May 2010 | WO |
| 2010030122 | Jul 2010 | WO |
| 2010101915 | Jan 2011 | WO |
| 2011018132 | Feb 2011 | WO |
| 2011018133 | Feb 2011 | WO |
| 2011024864 | Mar 2011 | WO |
| 2011054118 | May 2011 | WO |
| 2011079132 | Jun 2011 | WO |
| 2011107972 | Sep 2011 | WO |
| 2011108972 | Sep 2011 | WO |
| 2011117292 | Sep 2011 | WO |
| 2011123219 | Oct 2011 | WO |
| 2011132043 | Oct 2011 | WO |
| 2012012908 | Feb 2012 | WO |
| 2012065274 | May 2012 | WO |
| 2012097462 | Jul 2012 | WO |
| 2012098796 | Jul 2012 | WO |
| 2012101288 | Aug 2012 | WO |
| 2012175916 | Dec 2012 | WO |
| 2013018435 | Feb 2013 | WO |
| 2013033429 | Mar 2013 | WO |
| 2013055434 | Apr 2013 | WO |
| 2013082397 | Jun 2013 | WO |
| 2013103291 | Jul 2013 | WO |
| 2013131109 | Sep 2013 | WO |
| 2013167478 | Nov 2013 | WO |
| 2013177716 | Dec 2013 | WO |
| 2014041534 | Mar 2014 | WO |
| 2014046420 | Mar 2014 | WO |
| 2014118518 | Aug 2014 | WO |
| 2014160852 | Oct 2014 | WO |
| 2015023599 | Feb 2015 | WO |
| 2015052348 | Apr 2015 | WO |
| 2015068384 | May 2015 | WO |
| 2015169403 | Nov 2015 | WO |
| 2015170307 | Nov 2015 | WO |
| 2015197462 | Dec 2015 | WO |
| 2016051385 | Apr 2016 | WO |
| 2016055989 | Apr 2016 | WO |
| 2016071894 | May 2016 | WO |
| 2016103242 | Jun 2016 | WO |
| 2016116915 | Jul 2016 | WO |
| 2016124203 | Aug 2016 | WO |
| 2016139448 | Sep 2016 | WO |
| 2016166562 | Oct 2016 | WO |
| 2016167535 | Oct 2016 | WO |
| 2016191574 | Dec 2016 | WO |
| 2016200088 | Dec 2016 | WO |
| 2016200361 | Dec 2016 | WO |
| 2016204731 | Dec 2016 | WO |
| 2017001532 | Jan 2017 | WO |
| 2017001846 | Jan 2017 | WO |
| 2017075226 | May 2017 | WO |
| 2017152198 | Sep 2017 | WO |
| 2017153357 | Sep 2017 | WO |
| 2017162559 | Sep 2017 | WO |
| 2017205446 | Nov 2017 | WO |
| 2017209779 | Dec 2017 | WO |
| 2017210524 | Dec 2017 | WO |
| 2018022414 | Feb 2018 | WO |
| 2018044781 | Mar 2018 | WO |
| 2018056953 | Mar 2018 | WO |
| 2018090550 | May 2018 | WO |
| 2018138513 | Aug 2018 | WO |
| 2018144318 | Aug 2018 | WO |
| 2018144463 | Aug 2018 | WO |
| 2018150263 | Aug 2018 | WO |
| 2018150268 | Aug 2018 | WO |
| 2018152156 | Aug 2018 | WO |
| 2018183791 | Oct 2018 | WO |
| 2018150267 | Nov 2018 | WO |
| 2018235026 | Dec 2018 | WO |
| 2018235065 | Dec 2018 | WO |
| 2019004404 | Jan 2019 | WO |
| 2019041005 | Mar 2019 | WO |
| 2019044217 | Mar 2019 | WO |
| 2019044218 | Mar 2019 | WO |
| 2019044219 | Mar 2019 | WO |
| 2019050959 | Mar 2019 | WO |
| 2019065541 | Apr 2019 | WO |
| 2019096845 | May 2019 | WO |
| 2019150385 | Aug 2019 | WO |
| 2019161094 | Aug 2019 | WO |
| 2019188566 | Oct 2019 | WO |
| 2019190593 | Oct 2019 | WO |
| 2019212949 | Nov 2019 | WO |
| 2019212950 | Nov 2019 | WO |
| 2019212951 | Nov 2019 | WO |
| 2019212952 | Nov 2019 | WO |
| 2019212954 | Nov 2019 | WO |
| 2019212955 | Nov 2019 | WO |
| 2019212956 | Nov 2019 | WO |
| 2019214787 | Nov 2019 | WO |
| 2019214788 | Nov 2019 | WO |
| 2019226826 | Nov 2019 | WO |
| 2019239433 | Dec 2019 | WO |
| 2020000994 | Jan 2020 | WO |
| 2020020618 | Jan 2020 | WO |
| 2020038822 | Feb 2020 | WO |
| 2020088409 | May 2020 | WO |
| 2020049394 | Jun 2020 | WO |
| 2020120657 | Jun 2020 | WO |
| 2020152575 | Jul 2020 | WO |
| 2020182923 | Sep 2020 | WO |
| 2020204967 | Oct 2020 | WO |
| 2020205939 | Oct 2020 | WO |
| 2020209898 | Oct 2020 | WO |
| 2020242790 | Dec 2020 | WO |
| 2020251893 | Dec 2020 | WO |
| 2020256865 | Dec 2020 | WO |
| 2021007144 | Jan 2021 | WO |
| 2021007345 | Jan 2021 | WO |
| 2021010844 | Jan 2021 | WO |
| 2021016026 | Jan 2021 | WO |
| 2021016300 | Jan 2021 | WO |
| 2021025919 | Feb 2021 | WO |
| 2021034886 | Feb 2021 | WO |
| 2021041123 | Mar 2021 | WO |
| 2021046501 | Mar 2021 | WO |
| 2021086868 | May 2021 | WO |
| 2021094352 | May 2021 | WO |
| 2021094639 | May 2021 | WO |
| 2021097067 | May 2021 | WO |
| 2021102296 | May 2021 | WO |
| 2021107025 | Jun 2021 | WO |
| 2021138411 | Jul 2021 | WO |
| 2021138414 | Jul 2021 | WO |
| 2021154686 | Aug 2021 | WO |
| 2021155206 | Aug 2021 | WO |
| 2021170075 | Sep 2021 | WO |
| 2021173436 | Sep 2021 | WO |
| 2021188817 | Sep 2021 | WO |
| 2021195384 | Sep 2021 | WO |
| 2021205995 | Oct 2021 | WO |
| 2021207621 | Oct 2021 | WO |
| 2021211568 | Oct 2021 | WO |
| 2021211801 | Oct 2021 | WO |
| 2021211914 | Oct 2021 | WO |
| 2021216419 | Oct 2021 | WO |
| 2021216422 | Oct 2021 | WO |
| 2021231532 | Nov 2021 | WO |
| 2021247523 | Dec 2021 | WO |
| 2021257202 | Dec 2021 | WO |
| 2022006256 | Jan 2022 | WO |
| 2022031943 | Feb 2022 | WO |
| 2022035745 | Feb 2022 | WO |
| 2022051360 | Mar 2022 | WO |
| 2022054613 | Mar 2022 | WO |
| 2022066704 | Mar 2022 | WO |
| 2022067392 | Apr 2022 | WO |
| 2022069950 | Apr 2022 | WO |
| 2022071429 | Apr 2022 | WO |
| 2022076322 | Apr 2022 | WO |
| 2022076427 | Apr 2022 | WO |
| 2022086898 | Apr 2022 | WO |
| 2022090199 | May 2022 | WO |
| 2022098536 | May 2022 | WO |
| 2022099087 | May 2022 | WO |
| 2022101999 | May 2022 | WO |
| 2022115692 | Jun 2022 | WO |
| 2022125685 | Jun 2022 | WO |
| 2022140545 | Jun 2022 | WO |
| 2022145231 | Jul 2022 | WO |
| 2022150360 | Jul 2022 | WO |
| 2022150463 | Jul 2022 | WO |
| 2022159392 | Jul 2022 | WO |
| 2022170182 | Aug 2022 | WO |
| 2022182385 | Sep 2022 | WO |
| 2022187152 | Sep 2022 | WO |
| 2022192188 | Sep 2022 | WO |
| 2022192347 | Sep 2022 | WO |
| 2022204000 | Sep 2022 | WO |
| 2022216507 | Oct 2022 | WO |
| 2022222030 | Oct 2022 | WO |
| 2023286058 | Jan 2023 | WO |
| 2023014639 | Feb 2023 | WO |
| 2023014641 | Feb 2023 | WO |
| 2023018475 | Feb 2023 | WO |
| 2023023777 | Mar 2023 | WO |
| 2023034453 | Mar 2023 | WO |
| 2023038945 | Mar 2023 | WO |
| 2023038950 | Mar 2023 | WO |
| 2023049109 | Mar 2023 | WO |
| 2023049175 | Mar 2023 | WO |
| 2023086394 | May 2023 | WO |
| 2023149884 | Aug 2023 | WO |
| 2023149902 | Aug 2023 | WO |
| 2023149903 | Aug 2023 | WO |
| 2023154390 | Aug 2023 | WO |
| 2023191764 | Oct 2023 | WO |
| 2023244238 | Dec 2023 | WO |
| 2024058788 | Mar 2024 | WO |
| Entry |
|---|
| US 9,908,683 B2, 03/2018, Sandhausen et al. (withdrawn) |
| U.S. Appl. No. 17/662,700, filed May 10, 2022. |
| U.S. Appl. No. 63/008,112, filed Apr. 10, 2020. |
| Advisory Action for U.S. Appl. No. 14/722,613 mailed Mar. 4, 2019. |
| Advisory Action for U.S. Appl. No. 14/952,591 mailed Jun. 1, 2018. |
| Advisory Action for U.S. Appl. No. 15/238,427 mailed Apr. 10, 2019. |
| Advisory Action for U.S. Appl. No. 16/899,956 mailed Jul. 9, 2021. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jul. 2, 2021. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Feb. 16, 2022. |
| Advisory Action for U.S. Appl. No. 16/905,400 mailed Jun. 9, 2021. |
| Corrected International Search Report and Written Opinion for International Application No. PCT/US2017/043025 mailed Jan. 11, 2018. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/221,106 mailed Jul. 2, 2019. |
| Corrected Notice of Allowability for U.S. Appl. No. 15/612,325 mailed Mar. 17, 2021. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/330,657 mailed Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 14/722,613 mailed on Nov. 29, 2018. |
| Final Office Action for U.S. Appl. No. 14/947,759 mailed Apr. 8, 2016. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Feb. 23, 2018. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 1, 2019. |
| Final Office Action for U.S. Appl. No. 14/952,591 mailed Nov. 27, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Feb. 14, 2020. |
| Final Office Action for U.S. Appl. No. 15/171,968 mailed Mar. 19, 2019. |
| Final Office Action for U.S. Appl. No. 15/221,106 mailed Jan. 23, 2019. |
| Final Office Action for U.S. Appl. No. 15/238,427 mailed Jan. 2, 2019. |
| Final Office Action for U.S. Appl. No. 15/260,103 mailed Feb. 14, 2019. |
| Final Office Action for U.S. Appl. No. 15/612,325 mailed Sep. 17, 2020. |
| Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2021. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 10, 2022. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 26, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 6, 2021. |
| Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 9, 2021. |
| Final Office Action for U.S. Appl. No. 17/088,272 mailed May 25, 2021. |
| Final Office Action for U.S. Appl. No. 29/624,661 mailed Feb. 18, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2016/049274 mailed Dec. 1, 2016. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/035625 mailed Aug. 15, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2017/043025 mailed Oct. 18, 2017. |
| International Search Report and Written Opinion from International Application No. PCT/US2018/015968 mailed Apr. 6, 2018. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029608 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029609 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029610 mailed Sep. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029611 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029613 mailed Jul. 3, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029614 mailed Sep. 26, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2019/029616 mailed Aug. 30, 2019. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/023572 mailed Jul. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033064 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/033122 mailed Aug. 31, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/040860 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041242 mailed Nov. 17, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/041249 mailed Oct. 2, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/042262 mailed Oct. 14, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/043059 mailed Oct. 6, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/044024 mailed Nov. 12, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/046914 mailed Dec. 1, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/055680 mailed Dec. 15, 2020. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/057562 mailed Jan. 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/061563 mailed Feb. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/065234 mailed Apr. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067451 mailed Mar. 25, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067454 mailed Mar. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2020/067455 mailed Mar. 26, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015024 mailed May 18, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/015787 mailed May 27, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/023001 mailed Jun. 21, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/024162 mailed Jul. 8, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/026607 mailed Jul. 29, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027061 mailed Jul. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027104 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027314 mailed Jul. 6, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027422 mailed Aug. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027425 mailed Aug. 11, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027913 mailed Jul. 12, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/027917 mailed Aug. 19, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/035181 mailed Sep. 16, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/043893 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/044699 mailed Nov. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/045188 mailed Jan. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/047536 mailed Dec. 23, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048211 mailed Dec. 22, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/048661 mailed Feb. 14, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/056566 mailed Feb. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/060993 mailed Mar. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/062440 mailed Mar. 28, 2022. |
| Issue Notification for U.S. Appl. No. 14/952,591 mailed Jul. 28, 2021. |
| Issue Notification for U.S. Appl. No. 15/171,968 mailed Mar. 3, 2021. |
| Issue Notification for U.S. Appl. No. 15/221,106 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/238,427 mailed Jul. 24, 2019. |
| Issue Notification for U.S. Appl. No. 15/260,103 mailed Aug. 7, 2019. |
| Issue Notification for U.S. Appl. No. 15/611,587 mailed Feb. 20, 2019. |
| Issue Notification for U.S. Appl. No. 15/612,325 mailed Mar. 24, 2021. |
| Issue Notification for U.S. Appl. No. 29/624,661 mailed Aug. 4, 2021. |
| Non-Final Office Action for U.S. Appl. No. 14/592,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/722,613 mailed Jun. 13, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/947,759 mailed Mar. 17, 2016. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Aug. 1, 2017. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 20, 2020. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Mar. 21, 2019. |
| Non-Final Office Action for U.S. Appl. No. 14/952,591 mailed Sep. 28, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed May 11, 2020. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Aug. 20, 2019. |
| Non-Final Office Action for U.S. Appl. No. 15/171,968 mailed Jun. 12, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/221,106 mailed Jun. 5, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/238,427 mailed Aug. 8, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/260,103 mailed Sep. 26, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Dec. 29, 2017. |
| Non-Final Office Action for U.S. Appl. No. 15/611,587 mailed Jul. 13, 2018. |
| Non-Final Office Action for U.S. Appl. No. 15/612,325 mailed Mar. 19, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/245,726 mailed Jan. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Mar. 31, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 21, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Dec. 8, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Sep. 28, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Oct. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Oct. 16, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/899,956 mailed Sep. 2, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 25, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Oct. 5, 2021. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Apr. 27, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Dec. 2, 2020. |
| Non-Final Office Action for U.S. Appl. No. 16/905,400 mailed Jul. 22, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/088,272 mailed Jan. 25, 2021. |
| Non-Final Office Action for U.S. Appl. No. 17/330,657 mailed Aug. 11, 2021. |
| Non-Final Office Action for U.S. Appl. No. 29/624,661 mailed Jul. 18, 2019. |
| Non-Final Office Action for U.S. Appl. No. 29/694,002 mailed Jun. 24, 2020. |
| Non-Final Office Action for U.S. Appl. No. 29/741,751 mailed Jan. 18, 2022. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Apr. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 14/952,591 mailed Jul. 8, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Feb. 16, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/171,968 mailed Nov. 6, 2020. |
| Notice of Allowance for U.S. Appl. No. 15/221,106 mailed May 1, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/238,427 mailed May 23, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/260,103 mailed Jun. 7, 2019. |
| Notice of Allowance for U.S. Appl. No. 15/611,587 mailed Dec. 21, 2018. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Feb. 19, 2021. |
| Notice of Allowance for U.S. Appl. No. 15/612,325 mailed Jan. 21, 2021. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Apr. 19, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Aug. 5, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Mar. 4, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/088,272 mailed Nov. 24, 2021. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Mar. 16, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/330,657 mailed Nov. 26, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Apr. 28, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Jul. 10, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed May 14, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/624,661 mailed Sep. 29, 2020. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Apr. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Jan. 29, 2021. |
| Notice of Allowance for U.S. Appl. No. 29/694,002 mailed Oct. 16, 2020. |
| Notice to File Missing Parts for U.S. Appl. No. 17/179,116 mailed Mar. 3, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/433,773 mailed Dec. 7, 2021. |
| Restriction Requirement for U.S. Appl. No. 16/478,180 mailed May 25, 2021. |
| U.S. Appl. No. 14/625,469, filed Feb. 28, 2015. |
| U.S. Appl. No. 14/947,759, filed Nov. 20, 2015. |
| U.S. Appl. No. 14/952,591, filed Nov. 25, 2015. |
| U.S. Appl. No. 15/171,968, filed Jun. 2, 2016. |
| U.S. Appl. No. 15/221,106, filed Jul. 27, 2016. |
| U.S. Appl. No. 15/260,103, filed Sep. 8, 2016. |
| U.S. Appl. No. 15/384,196, filed Dec. 19, 2016. |
| U.S. Appl. No. 15/611,587, filed Jun. 1, 2017. |
| U.S. Appl. No. 15/612,325, filed Jun. 2, 2017. |
| U.S. Appl. No. 16/245,726, filed Jan. 11, 2019. |
| U.S. Appl. No. 16/369,676, filed Mar. 29, 2019. |
| U.S. Appl. No. 16/433,773, filed Jun. 6, 2019. |
| U.S. Appl. No. 16/449,039, filed Jun. 21, 2019. |
| U.S. Appl, No. 16/452,145, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/452,258, filed Jun. 25, 2019. |
| U.S. Appl. No. 16/478,180, filed Jul. 16, 2019. |
| U.S. Appl. No. 16/904,868, filed Jun. 18, 2020. |
| U.S. Appl. No. 16/905,400, filed Jun. 18, 2020. |
| U.S. Appl. No. 17/051,550, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,554, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,585, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/051,600, filed Oct. 29, 2020. |
| U.S. Appl. No. 17/088,272, filed Nov. 3, 2020. |
| U.S. Appl. No. 17/179,116, filed Feb. 18, 2021. |
| U.S. Appl. No. 17/330,657, filed May 26, 2021. |
| U.S. Appl. No. 17/378,015, filed Jul. 16, 2021. |
| U.S. Appl. No. 17/394,055, filed Aug. 4, 2021. |
| U.S. Appl. No. 17/412,864, filed Aug. 26, 2021. |
| U.S. Appl. No. 17/444,825, filed Aug. 10, 2021. |
| U.S. Appl. No. 17/446,256, filed Aug. 27, 2021. |
| U.S. Appl. No. 17/446,654, filed Sep. 1, 2021. |
| U.S. Appl. No. 17/447,123, filed Sep. 8, 2021. |
| U.S. Appl. No. 17/450,864, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/451,345, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/451,354, filed Oct. 19, 2021. |
| U.S. Appl. No. 17/453,260, filed Nov. 2, 2021. |
| U.S. Appl. No. 17/453,560, filed Nov. 4, 2021. |
| U.S. Appl. No. 17/461,036 mailed Aug. 30, 2021. |
| U.S. Appl. No. 17/494,578, filed Oct. 5, 2021. |
| U.S. Appl. No. 17/501,591, filed Oct. 14, 2021. |
| U.S. Appl. No. 17/595,747, filed Nov. 23, 2021. |
| U.S. Appl. No. 17/597,408, filed Jan. 5, 2022. |
| U.S. Appl. No. 17/597,673, filed Jan. 18, 2022. |
| U.S. Appl. No. 17/614,173, filed Nov. 24, 2021. |
| U.S. Appl. No. 17/631,619, filed Jan. 31, 2022. |
| U.S. Appl. No. 17/645,821, filed Dec. 23, 2021. |
| U.S. Appl. No. 17/646,771, filed Jan. 3, 2022. |
| U.S. Appl. No. 17/653,314, filed Mar. 3, 2022. |
| U.S. Appl. No. 17/653,920, filed Mar. 8, 2022. |
| U.S. Appl. No. 17/654,156, filed Mar. 9, 2022. |
| U.S. Appl. No. 17/655,464, filed Mar. 18, 2022. |
| U.S. Appl. No. 17/657,474, filed Mar. 31, 2022. |
| U.S. Appl. No. 17/754,736, filed Apr. 11, 2022. |
| U.S. Appl. No. 29/741,751, filed Jul. 15, 2020. |
| U.S. Appl. No. 61/955,537, filed Mar. 19, 2014. |
| U.S. Appl. No. 62/082,279, filed Nov. 20, 2014. |
| U.S. Appl. No. 62/084,078, filed Nov. 25, 2014. |
| U.S. Appl. No. 62/414,963, filed Oct. 31, 2016. |
| U.S. Appl. No. 62/452,437, filed Jan. 31, 2017. |
| U.S. Appl. No. 62/485,578, filed Apr. 14, 2017. |
| U.S. Appl. No. 62/665,297, filed May 1, 2018. |
| U.S. Appl. No. 62/665,302, filed May 1, 2018. |
| U.S. Appl. No. 62/665,317, filed May 1, 2018. |
| U.S. Appl. No. 62/665,321, filed May 1, 2018. |
| U.S. Appl. No. 62/665,331, filed May 1, 2018. |
| U.S. Appl. No. 62/665,335, filed May 1, 2018. |
| U.S. Appl. No. 62/853,279, filed May 28, 2019. |
| U.S. Appl. No. 62/853,889, filed May 29, 2019. |
| U.S. Appl. No. 62/864,656, filed Jun. 21, 2019. |
| U.S. Appl. No. 62/873,045, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/873,048, filed Jul. 11, 2019. |
| U.S. Appl. No. 62/876,500, filed Jul. 19, 2019. |
| U.S. Appl. No. 62/877,558, filed Jul. 23, 2019. |
| U.S. Appl. No. 62/883,172, filed Aug. 6, 2019. |
| U.S. Appl. No. 62/889,149, filed Aug. 20, 2019. |
| U.S. Appl. No. 62/923,279, filed Oct. 18, 2019. |
| U.S. Appl. No. 62/926,767, filed Oct. 28, 2019. |
| U.S. Appl. No. 62/935,337, filed Nov. 14, 2019. |
| U.S. Appl. No. 62/938,447, filed Nov. 21, 2019. |
| U.S. Appl. No. 62/949,187, filed Dec. 17, 2019. |
| U.S. Appl. No. 62/956,756, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,767, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/956,770, filed Jan. 3, 2020. |
| U.S. Appl. No. 62/967,977, filed Jan. 30, 2020. |
| U.S. Appl. No. 62/994,912, filed Mar. 26, 2020. |
| U.S. Appl. No. 63/011,445, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,487, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,571, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,657, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/011,760, filed Apr. 17, 2020. |
| U.S. Appl. No. 63/012,347, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/012,384, filed Apr. 20, 2020. |
| U.S. Appl. No. 63/030,685, filed May 27, 2020. |
| U.S. Appl. No. 63/033,310, filed Jun. 2, 2020. |
| U.S. Appl. No. 63/047,374, filed Jul. 2, 2020. |
| U.S. Appl. No. 63/061,241, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,244, filed Aug. 5, 2020. |
| U.S. Appl. No. 63/061,834, filed Aug. 6, 2020. |
| U.S. Appl. No. 63/064,017, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/064,126, filed Aug. 11, 2020. |
| U.S. Appl. No. 63/067,542, filed Aug. 19, 2020. |
| U.S. Appl. No. 63/071,438, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/071,821, filed Aug. 28, 2020. |
| U.S. Appl. No. 63/073,545, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/073,553, filed Sep. 2, 2020. |
| U.S. Appl. No. 63/074,051, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/074,066, filed Sep. 3, 2020. |
| U.S. Appl. No. 63/076,032, filed Sep. 9, 2020. |
| U.S. Appl. No. 63/076,474, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/076,477, filed Sep. 10, 2020. |
| U.S. Appl. No. 63/082,261, filed Sep. 23, 2020. |
| U.S. Appl. No. 63/088,506, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,511, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/088,539, filed Oct. 7, 2020. |
| U.S. Appl. No. 63/094,464, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,498, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,594, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,608, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,626, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/094,646, filed Oct. 21, 2020. |
| U.S. Appl. No. 63/109,066, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/109,084, filed Nov. 3, 2020. |
| U.S. Appl. No. 63/112,417, filed Nov. 11, 2020. |
| U.S. Appl. No. 63/119,161, filed Nov. 30, 2020. |
| U.S. Appl. No. 63/124,271, filed Dec. 11, 2020. |
| U.S. Appl. No. 63/133,892, filed Jan. 5, 2021. |
| U.S. Appl. No. 63/134,287, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,450, filed Jan. 6, 2021. |
| U.S. Appl. No. 63/134,631, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,632, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/134,754, filed Jan. 7, 2021. |
| U.S. Appl. No. 63/138,878, filed Jan. 19, 2021. |
| U.S. Appl. No. 63/146,946, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,013, filed Feb. 8, 2021. |
| U.S. Appl. No. 63/147,299, filed Feb. 9, 2021. |
| U.S. Appl. No. 63/148,723, filed Feb. 12, 2021. |
| U.S. Appl. No. 63/154,248, filed Feb. 26, 2021. |
| U.S. Appl. No. 63/155,395, filed Mar. 2, 2021. |
| U.S. Appl. No. 63/157,007, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/157,014, filed Mar. 5, 2021. |
| U.S. Appl. No. 63/159,142, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,186, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,210, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/159,280, filed Mar. 10, 2021. |
| U.S. Appl. No. 63/165,273, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/165,384, filed Mar. 24, 2021. |
| U.S. Appl. No. 63/171,165, filed Apr. 6, 2021. |
| U.S. Appl. No. 63/172,975, filed Apr. 9, 2021. |
| U.S. Appl. No. 63/181,695, filed Apr. 29, 2021. |
| U.S. Appl. No. 63/192,274, filed May 24, 2021. |
| U.S. Appl. No. 63/193,235, filed May 26, 2021. |
| U.S. Appl. No. 63/193,406, filed May 26, 2021. |
| U.S. Appl. No. 63/193,891, filed May 27, 2021. |
| U.S. Appl. No. 63/208,262, filed Jun. 8, 2021. |
| U.S. Appl. No. 63/214,551, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/214,570, filed Jun. 24, 2021. |
| U.S. Appl. No. 63/215,017, filed Jun. 25, 2021. |
| U.S. Appl. No. 63/228,244, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,252, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/228,258, filed Aug. 2, 2021. |
| U.S. Appl. No. 63/230,894, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/230,897, filed Aug. 9, 2021. |
| U.S. Appl. No. 63/238,457, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/238,477, filed Aug. 30, 2021. |
| U.S. Appl. No. 63/241,562, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,564, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/241,575, filed Sep. 8, 2021. |
| U.S. Appl. No. 63/246,972, filed Sep. 22, 2021. |
| U.S. Appl. No. 63/247,375, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,478, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/247,491, filed Sep. 23, 2021. |
| U.S. Appl. No. 63/299,208, filed Jan. 13, 2022. |
| Sage's Second Supplemental Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508, 10,226,375, 10,390,989, and U.S. Pat. No. 10,376,407, 292 pages. |
| Plaintiff's Identification of Claim Terms and Proposed Constructions, 3 pages. |
| Sage's Preliminary Identification of Claim Elements and Proposed Constructions for U.S. Pat. Nos. 8,287,508, 10,226,376, 10,390,989 and U.S. Pat. No. 10,376,407, 7 pages. |
| Corrected Certificate of Service, 2020, 2 pages. |
| Excerpts from the 508 (U.S. Pat. No. 8,278,508) Patent's Prosecution History, 2020, 99 pages. |
| Declaration of Diane K. Newman Curriculum Vitae, 2020, pp. 1-199. |
| Sage's Supplemental and Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; 10,390,989 and Initial Invalidity Contentions Regarding U.S. Pat. No. 10,376,407, Aug. 21, 2020, 277 pages. |
| Decision Granting Institution of Inter Partes Review for U.S. Pat. No. 8,287,508, Feb. 17, 2021, 39 pages. |
| Memorandum Order, Feb. 2021, 14 pgs. |
| Boehringer CareDry System—Second Generation for Non-Invasive Urinary Management for Females, Mar. 2021, 3 pgs. |
| PureWick's Response to Interrogatory No. 9 in PureWick, LLC v. Sage Products, LLC, Mar. 23, 2020, 6 pages. |
| Sage's Initial Invalidity Contentions Regarding U.S. Pat. Nos. 8,287,508; 10,226,375; and U.S. Pat. No. 10,390,989, May 29, 2020, 193 pages. |
| Defendant and Counterclaim Plaintiff Sage Products, LLC's Answer, Defenses, and Counterclaims To Plaintiff's Amended Complaint, Nov. 1, 2019. |
| Plaintiff's Opening Claim Construction Brief, Oct. 16, 2020, 26 pages. |
| “3 Devices Take Top Honors in Dare-To-Dream Medtech Design Contest”, R+D Digest, Nov. 2013, 1 page. |
| “Advanced Mission Extender Device (AMDX) Products”, Omni Medical Systems, Inc., 15 pages. |
| “AMXD Control Starter Kit Brochure”, https://www.omnimedicalsys.com/index.php?page=products, 8 pages. |
| “AMXDmax In-Flight Bladder Relief”, Omni Medical; Omni Medical Systems, Inc., 2015. |
| “AMXDX—Advanced Mission Extender Device Brochure”, Omni Medical, 2 pages. |
| “External Urine Management for Female Anatomy”, https://www.stryker.com/us/en/sage/products/sage-primafit.html, Jul. 2020, 4 pages. |
| “High Absorbancy Cellulose Acetate Electrospun Nanofibers for Feminine Hygiene Application”, https://www.sciencedirect.com/science/article/abs/pii/S2352940716300701?via%3Dihub, Jul. 2016, 3 pages. |
| “How Period Panties Work”, www.shethinx.com/pages/thinx-itworks, 2020, 10 pages. |
| “Hydrogel properties of electrospun polyvinylpyrrolidone and polyvinylpyrrolidone/poly(acrylic acid) blend nanofibers”, https://pubs.rsc.org/en/content/articlelanding/2015/ra/c5ra07514a#!divAbstract, 2015, 5 pages. |
| “In Flight Bladder Relief”, Omni Medical, 14 pages. |
| “Making Women's Sanitary Products Safer and Cheaper”, https://www.elsevier.com/connect/making-womens-sanitary-products-safer-and-cheaper, Sep. 2016, 10 pages. |
| “Novel Nanofibers Make Safe and Effective Absorbent for Sanitary Products”, https://www.materialstoday.com/nanomaterials/news/nanofibers-make-safe-and-effective-absorbent/, Oct. 2016, 3 pages. |
| “Research and Development Work Relating to Assistive Technology Jun. 2005”, British Department of Health, Nov. 2006, 40 pages. |
| “Rising Warrior Insulated Gallon Jug Cover”, https://www.amazon.com/Rising-Warrior-Insulated-Sleeve, 2021, 2 pages. |
| “Step by Step How Ur24 WorksHome”, http://medicalpatentur24.com, Aug. 30, 2017, 4 pages. |
| “Underwear that absorbs your period”, Thinx!, 7 pages. |
| “Urine Bag Cover-Catheter Bag Cover 2000 ml Volume-Medline Style-Multiple Sclerosis-Spine Injury-Suprapublic Catheter-Bladder Incontinence”, https://www.etsy.com/listing/1142934658/urine-bag-cover-caatheter-bag-cover-2000, 2022, 1 page. |
| “User & Maintenance Guide”, Omni Medical, 2007, 16 pages. |
| “Vinyl Dust Cover, Janome #741811000, Janome, Sewing Parts Online”, https://www.sewingpartsonline.com/vinyl-dust-cover-janome-74181000, 2020, 2 pages. |
| “Winners Announced for Dare-to-Dream Medtech Design Challenge”, https://www.mddionline.com/design-engineering/winners-announced-dare-dream-medtech-design-challenge, 2014, 4 pages. |
| Ali , “Sustainability Assessment: Seventh Generation Diapers versus gDiapers”, The University of Vermont, Dec. 6, 2011, pp. 1-31. |
| Autumn , et al., “Frictional adhesion: a new angle on gecko attachment”, The Journal of Experimental Biology, 2006, pp. 3569-3579. |
| CAñas , et al., “Effect of nano- and micro-roughness on adhesion of bioinspired micropatterned surfaces”, Acta Biomaterialia 8, 2012, pp. 282-288. |
| Chaudhary , et al., “Bioinspired dry adhesive: Poly(dimethylsiloxane) grafted with poly(2-ethylhexyl acrylate) brushes”, European Polymer Journal, 2015, pp. 432-440. |
| Dai , et al., “Non-sticky and Non-slippery Biomimetic Patterned Surfaces”, Journal of Bionic Engineering, Mar. 2020, pp. 326-334. |
| Espinoza-Ramirez , “Nanobiodiversity and Biomimetic Adhesives Development: From Nature to Production and Application”, Journal of Biomaterials and Nanobiotechnology, pp. 78-101, 2019. |
| Hollister , “Female Urinary and Pouch and Male Urinary Pouch Brochure”, 2011, 1 page. |
| Hollister , “Male Urinary Pouch External Collection Device”, http://www.hollister.com/en/products/Continence-Care-Products/Urine-Collectors/Urine-Collection-Accessories/Male-Urinary-Pouch-External-Collection-Device. |
| Hollister , “Retracted Penis Pouch by Hollister”, Vitality Medical.com, 6 pages. |
| Hwang , et al., “Multifunctional Smart Skin Adhesive Patches for Advanced Health Care”, Adv. Healthcare Mater, 2018, pp. 1-20. |
| Jagota , et al., “Adhesion, friction, and compliance of bio-mimetic and bio-inspired structured interfaces”, Materials Science and Engineering, 2011, pp. 253-292. |
| Jeong , et al., “A nontransferring dry adhesive with hierarchical polymer nanohairs”, PNAS, Apr. 7, 2009, pp. 5639-5644. |
| Jeong , et al., “Nanohairs and nanotubes: Efficient structural elements for gecko-inspired artificial dry adhesives”, Science Direct, 2009, pp. 335-346. |
| Karp , et al., “Dry solution to a sticky problem”, Nature., 2011, pp. 42-43. |
| Lee , et al., “Continuous Fabrication of Wide-Tip Microstructures for Bio-Inspired Dry Adhesives via Tip Inking Process”, Journal of Chemistry, Jan. 2, 2019, pp. 1-5. |
| MacAulay , et al., “A Noninvasive Continence Management System: Development and Evaluation of a Novel Toileting Device for Women”, The Wound, Ostomy and Continence Nurses Society, 2007, pp. 641-648. |
| Newman , et al., “The Urinary Incontinence Sourcebook”, Petition for Interparties Review, 1997, 23 pages. |
| Newton , et al., “Measuring Safety, Effectiveness and Ease of Use of PureWick in the Management of Urinary Incontinence in Bedbound Women: Case Studies”, Jan. 8, 2016, 11 pages. |
| Parmar , “10 Finalists Chosen for Dare-to-Dream Medtech Design Challenge (PureWick)”, Design Services, Nov. 10, 2014, 3 pages. |
| Parness , et al., “A microfabricated wedge-shaped adhesive array displaying gecko-like dynamic adhesion, directionality”, J.R. Soc. Interface, 2009, pp. 1223-1232. |
| Purewick , “Incontinence Relief for Women”, Presentation, Sep. 23, 2015, 7 pages. |
| Pytlik , “Super Absorbent Polymers”, University of Buffalo. |
| Sachtman , “New Relief for Pilots? It Depends”, Wired, 2008, 2 pages. |
| Tsipenyuk , et al., “Use of biomimetic hexagonal surface texture in friction against lubricated skin”, Journal of The Royal Society—Interface, 2014, pp. 1-6. |
| Advisory Action for U.S. Appl. No. 16/245,726 mailed Apr. 19, 2023. |
| Advisory Action for U.S. Appl. No. 16/369,676 mailed Mar. 24, 2023. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Feb. 15, 2023. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Oct. 26, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 21, 2022. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Sep. 7, 2023. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jun. 15, 2022. |
| Advisory Action for U.S. Appl. No. 17/051,550 mailed Sep. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Aug. 25, 2023. |
| Advisory Action for U.S. Appl. No. 17/662,700 mailed Jan. 30, 2023. |
| Final Office Action for U.S. Appl. No. 16/245,726 mailed Nov. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Aug. 31, 2023. |
| Final Office Action for U.S. Appl. No. 16/369,676 mailed Dec. 5, 2022. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 25, 2022. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Aug. 1, 2022. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 14, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Jun. 22, 2022. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed May 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Mar. 9, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,550 mailed May 23, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 27, 2023. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Jun. 15, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Sep. 19, 2023. |
| Final Office Action for U.S. Appl. No. 17/448,811 mailed Aug. 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed May 3, 2023. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Sep. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/655,464 mailed Sep. 1, 2023. |
| Final Office Action for U.S. Appl. No. 17/662,700 mailed Sep. 30, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/IB2021/057173 mailed Nov. 5, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/039866 mailed Oct. 7, 2021. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/049404 mailed Jan. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/051456 mailed Jan. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/053593 mailed Apr. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2021/055515 mailed Jan. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011108 mailed Apr. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011281 mailed Apr. 25, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011419 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/011421 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/012794 mailed May 3, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014285 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/014749 mailed Sep. 28, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015026 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015045 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015073 mailed Sep. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015418 mailed Nov. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015420 mailed Nov. 18, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015471 mailed May 16, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015492 mailed Apr. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/015781 mailed May 6, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/016942 mailed Jun. 8, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018159 mailed Dec. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/018170 mailed May 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019254 mailed Jun. 7, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/019480 mailed Jun. 13, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/021103 mailed Jun. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/022111 mailed Oct. 26, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/023594 mailed Jul. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/026667 mailed Aug. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/030685 mailed Oct. 31, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/031032 mailed Sep. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/032424 mailed Oct. 11, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034457 mailed Oct. 12, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/034744 mailed Dec. 9, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039018 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039022 mailed Jan. 10, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039711 mailed Jan. 12, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/039714 mailed Nov. 22, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041085 mailed Mar. 16, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/041688 mailed Nov. 21, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042719 mailed Dec. 5, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/042725 mailed Dec. 19, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/043818 mailed Mar. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044107 mailed Dec. 23, 2022. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044208 mailed May 8, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044212 mailed Jan. 20, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/044243 mailed Feb. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/049300 mailed Jun. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2022/050909 mailed Jul. 24, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/012696 mailed Jul. 6, 2023. |
| Issue Notification for U.S. Appl. No. 16/899,956 mailed Mar. 29, 2023. |
| Issue Notification for U.S. Appl. No. 16/905,400 mailed Nov. 30, 2022. |
| Issue Notification for U.S. Appl. No. 17/088,272 mailed Jun. 15, 2022. |
| Issue Notification for U.S. Appl. No. 17/330,657 mailed Jun. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Apr. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/449,039 mailed Apr. 27, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Mar. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Apr. 26, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Dec. 20, 2022. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 15, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,399 mailed Aug. 18, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Dec. 15, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Mar. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Mar. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/326,980 mailed Jul. 11, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Feb. 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Apr. 13, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Sep. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Mar. 1, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 10, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Dec. 7, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed May 3, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/453,260 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/501,591 mailed Apr. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Jul. 5, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Apr. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 14, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/657,474 mailed Sep. 12, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/662,700 mailed Jul. 22, 2022. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jun. 29, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 8, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/139,523 mailed Aug. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Sep. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/245,726 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Dec. 15, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Aug. 10, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/899,956 mailed Dec. 1, 2022. |
| Notice of Allowance for U.S. Appl. No. 16/905,400 mailed Aug. 17, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Jul. 6, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Feb. 22, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Jun. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/461,036 mailed Oct. 6, 2022. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jul. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 28, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/663,046 mailed Jan. 30, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Jul. 24, 2023. |
| Notice of Allowance for U.S. Appl. No. 29/741,751 mailed Jun. 9, 2022. |
| Restriction Requirement for U.S. Appl. No. 17/051,600 mailed Sep. 21, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/326,980 mailed Mar. 20, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/446,256 mailed Jan. 23, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/645,821 mailed Jul. 12, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/646,771 mailed Apr. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 17/657,474 mailed Jun. 30, 2023. |
| Text Messages to Lorena Eckert Re Prototype PureWick Holder dated Apr. 16, 2022. |
| U.S. Appl. No. 17/663,046, filed May 12, 2022. |
| U.S. Appl. No. 17/664,487, filed May 23, 2022. |
| U.S. Appl. No. 17/664,914, filed May 25, 2022. |
| U.S. Appl. No. 17/749,340, filed May 20, 2022. |
| U.S. Appl. No. 17/756,201, filed May 19, 2022. |
| U.S. Appl. No. 17/758,152, filed Jun. 29, 2022. |
| U.S. Appl. No. 17/758,316, filed Jul. 1, 2022. |
| U.S. Appl. No. 17/759,697, filed Jul. 28, 2022. |
| U.S. Appl. No. 17/878,268, filed Aug. 1, 2022. |
| U.S. Appl. No. 17/907,125, filed Sep. 23, 2022. |
| U.S. Appl. No. 17/912,147, filed Sep. 16, 2022. |
| U.S. Appl. No. 17/929,887, filed Sep. 6, 2022. |
| U.S. Appl. No. 17/930,238, filed Sep. 7, 2022. |
| U.S. Appl. No. 17/933,590, filed Sep. 20, 2022. |
| U.S. Appl. No. 17/996,064, filed Oct. 12, 2022. |
| U.S. Appl. No. 17/996,155, filed Oct. 13, 2022. |
| U.S. Appl. No. 17/996,253, filed Oct. 14, 2022. |
| U.S. Appl. No. 17/996,468, filed Oct. 18, 2022. |
| U.S. Appl. No. 17/996,556, filed Oct. 19, 2022. |
| U.S. Appl. No. 18/003,029, filed Dec. 22, 2022. |
| U.S. Appl. No. 18/006,807, filed Jan. 25, 2023. |
| U.S. Appl. No. 18/007,105, filed Jan. 27, 2023. |
| U.S. Appl. No. 18/041,109, filed Feb. 9, 2023. |
| U.S. Appl. No. 18/042,842, filed Feb. 24, 2023. |
| U.S. Appl. No. 18/043,618, filed Mar. 1, 2023. |
| U.S. Appl. No. 18/115,444, filed Feb. 28, 2023. |
| U.S. Appl. No. 18/134,857, filed Apr. 14, 2023. |
| U.S. Appl. No. 18/140,163, filed Apr. 27, 2023. |
| U.S. Appl. No. 18/140,751, filed Apr. 28, 2023. |
| U.S. Appl. No. 18/164,800, filed Feb. 6, 2023. |
| U.S. Appl. No. 18/198,464, filed May 17, 2023. |
| U.S. Appl. No. 18/246,121, filed Mar. 21, 2023. |
| U.S. Appl. No. 18/247,986, filed Apr. 5, 2023. |
| U.S. Appl. No. 18/259,626, filed Jun. 28, 2023. |
| U.S. Appl. No. 18/260,122, filed Jun. 30, 2023. |
| U.S. Appl. No. 18/260,391, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/260,394, filed Jul. 5, 2023. |
| U.S. Appl. No. 18/263,800, filed Aug. 1, 2023. |
| U.S. Appl. No. 18/264,004, filed Aug. 2, 2023. |
| U.S. Appl. No. 18/265,736, filed Jun. 7, 2023. |
| U.S. Appl. No. 18/299,788, filed Apr. 13, 2023. |
| U.S. Appl. No. 18/335,579, filed Jun. 15, 2023. |
| U.S. Appl. No. 18/373,424, filed Sep. 27, 2023. |
| U.S. Appl. No. 18/376,274, filed Oct. 3, 2023. |
| U.S. Appl. No. 18/548,152, filed Aug. 28, 2023. |
| U.S. Appl. No. 18/549,387, filed Sep. 7, 2023. |
| U.S. Appl. No. 18/549,658, filed Sep. 8, 2023. |
| U.S. Appl. No. 18/553,625, filed Oct. 2, 2023. |
| U.S. Appl. No. 62/967,158, filed Jan. 26, 2020. |
| U.S. Appl. No. 62/991,754, filed Mar. 19, 2020. |
| U.S. Appl. No. 63/150,640, filed Feb. 18, 2021. |
| U.S. Appl. No. 63/191,558, filed May 21, 2021. |
| U.S. Appl. No. 63/192,289, filed May 24, 2021. |
| U.S. Appl. No. 63/241,328, filed Sep. 7, 2021. |
| U.S. Appl. No. 63/308,190, filed Feb. 9, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 2, Mar. 29, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 3, Mar. 30, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 4, Mar. 31, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 5, Apr. 1, 2022. |
| PureWick Corporation v. Sage Products, LLC Transcripts vol. 1, Mar. 28, 2022. |
| “AMXD Control Starter Kit”, Omni Medical Systems, Inc., 1 page. |
| “AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical, Jan. 11, 2010, 10 pages. |
| “AMXDmax Development History 2002-2014”, Omni Medical Systems, Inc., 2 pages. |
| “Combat Force Multiplier in Flight Bladder Relief Cockpit Essential Equipment Brochure”, Omni Medical, 20 pages. |
| “GSA Price List”, Omni Medical, Apr. 2011, 2 pages. |
| “How is Polypropylene Fiber Made”, https:www.yarnsandfibers.com/textile-resources/synthetic-fibers/polypropylene-fiber/polypropylene-fiber-production-raw-materials/how-is-polypropylene-fiber-made/ last accessed 2020, Oct. 7, 2020, 3 pages. |
| “Letter to Mark Harvie of Omni Measurement Systems”, Department of Veterans Affairs, Nov. 1, 2007, 11 pages. |
| “Revised AMXDmax Advanced Mission Extender Device User & Maintenance Guide”, Omni Medical Systems, Oct. 8, 2019, 52 pages. |
| Merriam-Webster Dictionary, “Embed Definition & Meaning”, https://www.merriam-webster.com/dictionary/embed last accessed Aug. 3, 2023, 2003. |
| Pieper, et al., “An external urine-collection device for women: A clinical trial”, Journal of ER Nursing, vol. 20, No. 2, Mar./Apr. 1993, pp. 51-55. |
| Vinas, “A Solution For An Awkward—But Serious—Subject”, http://www.aero-news.net/index.cfm?do=main.textpost&id=69ae2bb1-838b-4098-a7b5-7flbb2505688 last accessed Feb. 8, 2021. |
| Advisory Action for U.S. Appl. No. 16/433,773 mailed Dec. 29, 2023. |
| Advisory Action for U.S. Appl. No. 16/449,039 mailed Jan. 25, 2024. |
| Advisory Action for U.S. Appl. No. 16/904,868 mailed Jan. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/051,585 mailed Oct. 17, 2023. |
| Advisory Action for U.S. Appl. No. 17/179,116 mailed Jan. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,256 mailed Dec. 8, 2023. |
| Advisory Action for U.S. Appl. No. 17/448,811 mailed Nov. 15, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Oct. 20, 2023. |
| Advisory Action for U.S. Appl. No. 17/451,354 mailed Jan. 30, 2024. |
| Advisory Action for U.S. Appl. No. 17/453,260 mailed Dec. 22, 2023. |
| Advisory Action for U.S. Appl. No. 17/501,591 mailed Feb. 22, 2024. |
| Advisory Action for U.S. Appl. No. 17/646,771 mailed Feb. 29, 2024. |
| Advisory Action for U.S. Appl. No. 17/653,137 mailed Dec. 1, 2023. |
| Advisory Action for U.S. Appl. No. 17/655,464 mailed Dec. 13, 2023. |
| Advisory Action for U.S. Appl. No. 18/164,800 mailed Feb. 12, 2024. |
| Communication of Notice of Opposition of European Application No. 17807547.9 mailed Jan. 5, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 16/369,676 mailed Dec. 7, 2023. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/326,980 mailed Feb. 8, 2024. |
| Final Office Action for U.S. Appl. No. 16/433,773 mailed Oct. 10, 2023. |
| Final Office Action for U.S. Appl. No. 16/449,039 mailed Nov. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/452,258 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 16/478,180 mailed Feb. 28, 2024. |
| Final Office Action for U.S. Appl. No. 16/904,868 mailed Nov. 2, 2023. |
| Final Office Action for U.S. Appl. No. 17/051,399 mailed Jan. 8, 2024. |
| Final Office Action for U.S. Appl. No. 17/179,116 mailed Oct. 31, 2023. |
| Final Office Action for U.S. Appl. No. 17/446,654 mailed Jan. 31, 2024. |
| Final Office Action for U.S. Appl. No. 17/450,864 mailed Dec. 28, 2023. |
| Final Office Action for U.S. Appl. No. 17/451,354 mailed Oct. 30, 2023. |
| Final Office Action for U.S. Appl. No. 17/453,260 mailed Oct. 5, 2023. |
| Final Office Action for U.S. Appl. No. 17/501,591 mailed Nov. 14, 2023. |
| Final Office Action for U.S. Appl. No. 17/646,771 mailed Dec. 21, 2023. |
| Final Office Action for U.S. Appl. No. 17/663,330 mailed Dec. 12, 2023. |
| Final Office Action for U.S. Appl. No. 17/664,487 mailed Jan. 4, 2024. |
| Final Office Action for U.S. Appl. No. 18/139,523 mailed Dec. 22, 2023. |
| Final Office Action for U.S. Appl. No. 18/140,751 mailed Jan. 17, 2024. |
| Final Office Action for U.S. Appl. No. 18/164,800 mailed Dec. 6, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/018474 mailed Sep. 11, 2023. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/024805 mailed Dec. 14, 2023. |
| Issue Notification for U.S. Appl. No. 16/245,726 mailed Oct. 18, 2023. |
| Issue Notification for U.S. Appl. No. 17/461,036 mailed Oct. 11, 2023. |
| Issue Notification for U.S. Appl. No. 17/663,046 mailed Dec. 20, 2023. |
| Issue Notification for U.S. Appl. No. 18/299,788 mailed Feb. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/369,676 mailed Feb. 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/433,773 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/452,145 mailed Nov. 2, 2023. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Nov. 7, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,550 mailed Oct. 24, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/051,585 mailed Jan. 8, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/051,600 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/179,116 mailed Feb. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/444,792 mailed Nov. 17, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/446,256 mailed Feb. 13, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/447,123 mailed Jan. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/448,811 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jan. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/453,560 mailed Oct. 16, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/645,821 mailed Oct. 25, 2023. |
| Non-Final Office Action for U.S. Appl. No. 17/653,137 mailed Jan. 18, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/664,914 mailed Jan. 31, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/808,354 mailed Nov. 28, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/134,857 mailed Jan. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/140,163 mailed Nov. 9, 2023. |
| Non-Final Office Action for U.S. Appl. No. 18/198,464 mailed Dec. 7, 2023. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Nov. 14, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 7, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Oct. 18, 2023. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Jan. 29, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,560 mailed Jan. 31, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Nov. 15, 2023. |
| Notice of Allowance for U.S. Appl. No. 18/299,788 mailed Nov. 6, 2023. |
| Restriction Requirement for U.S. Appl. No. 18/134,857 mailed Oct. 23, 2023. |
| Submission in Opposition Proceedings for European Application No. 17807547.9 filed Jan. 10, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,550 mailed Feb. 21, 2024. |
| Supplemental Notice of Allowance for U.S. Appl. No. 17/051,554 mailed Feb. 14, 2024. |
| U.S. Appl. No. 17/451,719, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/294,370, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/294,403, filed Feb. 1, 2024. |
| U.S. Appl. No. 18/389,009, filed Nov. 13, 2023. |
| U.S. Appl. No. 18/415,080, filed Jan. 17, 2024. |
| U.S. Appl. No. 18/426,795, filed Jan. 30, 2024. |
| U.S. Appl. No. 18/556,945, filed Oct. 24, 2023. |
| U.S. Appl. No. 18/558,502, filed Nov. 1, 2023. |
| U.S. Appl. No. 18/562,626, filed Nov. 20, 2023. |
| U.S. Appl. No. 18/563,672, filed Nov. 22, 2023. |
| U.S. Appl. No. 18/569,711, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/569,778, filed Dec. 13, 2023. |
| U.S. Appl. No. 18/584,002, filed Feb. 22, 2024. |
| U.S. Appl. No. 18/681,987, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/682,006, filed Feb. 7, 2024. |
| U.S. Appl. No. 18/687,117, filed Feb. 27, 2024. |
| U.S. Appl. No. 18/688,023, filed Feb. 29, 2024. |
| U.S. Appl. No. 63/596,012, filed Nov. 3, 2023. |
| U.S. Appl. No. 63/608,553, filed Dec. 11, 2023. |
| Wikipedia Article, “Zylinder (Geometrie)”, https://de.wikipedia.org/w/index.php?title=Zylinder (Geometrie)&oldid=154862081, version of Jun. 1, 2016, 7 pages. |
| Advisory Action for U.S. Appl. No. 16/452,258 mailed Apr. 8, 2024. |
| Advisory Action for U.S. Appl. No. 16/478,180 mailed Jun. 7, 2024. |
| Advisory Action for U.S. Appl. No. 17/444,792 mailed Jul. 8, 2024. |
| Advisory Action for U.S. Appl. No. 17/446,654 mailed Apr. 15, 2024. |
| Advisory Action for U.S. Appl. No. 17/450,864 mailed Mar. 21, 2024. |
| Advisory Action for U.S. Appl. No. 17/451,345 mailed Jul. 3, 2024. |
| Advisory Action for U.S. Appl. No. 17/645,821 mailed Jul. 2, 2024. |
| Advisory Action for U.S. Appl. No. 17/664,487 mailed Mar. 13, 2024. |
| Advisory Action for U.S. Appl. No. 17/808,354 mailed Jun. 12, 2024. |
| Advisory Action for U.S. Appl. No. 18/139,523 mailed Apr. 24, 2024. |
| Advisory Action for U.S. Appl. No. 18/140,163 mailed Jun. 3, 2024. |
| Advisory Action for U.S. Appl. No. 18/140,751 mailed Apr. 24, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/501,591 mailed Aug. 9, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed Mar. 13, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/657,474 mailed May 14, 2024. |
| Corrected Notice of Allowability for U.S. Appl. No. 17/664,914 mailed Aug. 9, 2024. |
| Final Office Action for U.S. Appl. No. 17/051,585 mailed Jul. 5, 2024. |
| Final Office Action for U.S. Appl. No. 17/051,600 mailed Jun. 27, 2024. |
| Final Office Action for U.S. Appl. No. 17/444,792 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/446,256 mailed Aug. 7, 2024. |
| Final Office Action for U.S. Appl. No. 17/447,123 mailed May 14, 2024. |
| Final Office Action for U.S. Appl. No. 17/451,345 mailed Apr. 18, 2024. |
| Final Office Action for U.S. Appl. No. 17/645,821 mailed Apr. 3, 2024. |
| Final Office Action for U.S. Appl. No. 17/653,137 mailed Aug. 7, 2024. |
| Final Office Action for U.S. Appl. No. 17/653,920 mailed Aug. 14, 2024. |
| Final Office Action for U.S. Appl. No. 17/808,354 mailed Apr. 10, 2024. |
| Final Office Action for U.S. Appl. No. 18/134,857 mailed Jul. 25, 2024. |
| Final Office Action for U.S. Appl. No. 18/140,163 mailed Mar. 27, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025192 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/025939 mailed Feb. 7, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030365 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/030373 mailed Mar. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031433 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/031740 mailed Mar. 4, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/036238 mailed Jul. 22, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/036868 mailed Jun. 5, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/075507 mailed Jun. 13, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/077168 mailed Jun. 24, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/077208 mailed May 10, 2024. |
| International Search Report and Written Opinion from International Application No. PCT/US2023/080680 mailed Jul. 22, 2024. |
| Issue Notification for U.S. Appl. No. 16/449,039 mailed Jun. 19, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,550 mailed Mar. 13, 2024. |
| Issue Notification for U.S. Appl. No. 17/051,554 mailed Mar. 6, 2024. |
| Issue Notification for U.S. Appl. No. 17/326,980 mailed Jul. 10, 2024. |
| Issue Notification for U.S. Appl. No. 17/448,811 mailed Jul. 3, 2024. |
| Issue Notification for U.S. Appl. No. 17/453,260 mailed Jul. 10, 2024. |
| Issue Notification for U.S. Appl. No. 17/453,560 mailed Aug. 7, 2024. |
| Issue Notification for U.S. Appl. No. 17/657,474 mailed Jun. 19, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/452,258 mailed Jun. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/478,180 mailed Aug. 7, 2024. |
| Non-Final Office Action for U.S. Appl. No. 16/904,868 mailed Mar. 12, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/378,015 mailed Jul. 5, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/446,654 mailed Jun. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/450,864 mailed May 29, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,345 mailed Jul. 25, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/451,354 mailed Apr. 4, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/595,747 mailed Jun. 7, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/597,408 mailed Aug. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/597,673 mailed Mar. 20, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/646,771 mailed Apr. 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/653,920 mailed Mar. 15, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/655,464 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/663,330 mailed Jul. 1, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/664,487 mailed Jun. 17, 2024. |
| Non-Final Office Action for U.S. Appl. No. 17/749,340 mailed Aug. 14, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/003,029 mailed Mar. 26, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/140,751 mailed Jun. 21, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/164,800 mailed Mar. 22, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/389,009 mailed May 24, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/426,795 mailed Aug. 9, 2024. |
| Non-Final Office Action for U.S. Appl. No. 18/451,080 mailed Jul. 30, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/369,676 mailed Jun. 17, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/449,039 mailed Mar. 28, 2024. |
| Notice of Allowance for U.S. Appl. No. 16/452,145 mailed Jul. 11, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/326,980 mailed Apr. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/447,123 mailed Jul. 26, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/448,811 mailed Jun. 14, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/453,260 mailed Apr. 8, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/501,591 mailed Jul. 31, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed Mar. 5, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/657,474 mailed May 2, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Jun. 12, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/662,700 mailed Mar. 6, 2024. |
| Notice of Allowance for U.S. Appl. No. 17/664,914 mailed Jul. 26, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Apr. 17, 2024. |
| Notice of Allowance for U.S. Appl. No. 18/198,464 mailed Jul. 30, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/527,769 mailed Jun. 17, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/625,941 mailed Aug. 7, 2024. |
| Restriction Requirement for U.S. Appl. No. 17/667,097 mailed Mar. 20, 2024. |
| U.S. Appl. No. 17/013,822, filed Sep. 7, 2020. |
| U.S. Appl. No. 17/444,792, filed Aug. 10, 2021. |
| U.S. Appl. No. 18/249,577, filed Oct. 19, 2021. |
| U.S. Appl. No. 18/610,523, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/662,216, filed May 13, 2024. |
| U.S. Appl. No. 18/693,638, filed Mar. 20, 2024. |
| U.S. Appl. No. 18/694,090, filed Mar. 21, 2024. |
| U.S. Appl. No. 18/728,604, filed Jul. 12, 2024. |
| U.S. Appl. No. 18/757,964, filed Jun. 28, 2024. |
| U.S. Appl. No. 18/758,025, filed Jun. 28, 2024. |
| U.S. Appl. No. 18/834,115, filed Jul. 29, 2024. |
| U.S. Appl. No. 18/834,176, filed Jul. 29, 2024. |
| U.S. Appl. No. 18/834,340, filed Jul. 30, 2024. |
| U.S. Appl. No. 18/835,068, filed Aug. 1, 2024. |
| U.S. Appl. No. 18/835,444, filed Aug. 2, 2024. |
| U.S. Appl. No. 18/836,204, filed Aug. 6, 2024. |
| U.S. Appl. No. 63/561,893, filed Dec. 11, 2023. |
| U.S. Appl. No. 63/568,615, filed Mar. 22, 2024. |
| U.S. Appl. No. 63/683,428, filed Aug. 15, 2024. |
| “Oblong”, Cambridge Dictionary, https://dictionary.cambridge.org/dictionary/english/oblong, 2024, 1 page. |
| Britannica, “Polyolefin”, Britannica Online Encyclopedia, T. Editors of Encyclopaedia, https://www.britannica.com/science/polyolefin, Jul. 26, 2012. |
| Martin, et al., “Chapter 5 Applications of Polyethylene Oxide (POLYOX) in Hydrophilic Matrices”, Hydrophilic Matrix Tablets for Oral Controlled Release, AAPS Advances in the Pharmaceutical Sciences vol. 16, 2014, pp. 123-141. |
| Wikipedia Article, “Decibel”, https://web.archive.org/web/2020041521917/https://en.wikipedia/org/wiki/Decibel last accessed Mar. 11, 2024, 21 pages. |
| Wikipedia Article, “Fiberglass”, https://web.archive.org.web/20200309194847/https://en.wikipedia.org/wiki/Fiberglass last accessed Mar. 11, 2024. |
| Number | Date | Country | |
|---|---|---|---|
| 20220347004 A1 | Nov 2022 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63181709 | Apr 2021 | US |
